{"data":{"filter_options":{"titles":[{"name":"Managing Partner Atlanta Office","value":"Managing Partner Atlanta Office"},{"name":"Partner","value":"Partner"},{"name":"Partner / Head of Pro Bono","value":"Partner / Head of Pro Bono"},{"name":"Partner / Chief Operating Officer","value":"Partner / Chief Operating Officer"},{"name":"Partner / General Counsel","value":"Partner / General Counsel"},{"name":"Partner / Dir. E-Discovery Ops","value":"Partner / Dir. E-Discovery Ops"},{"name":"Partner / Chairman, Saudi Arabia Practice","value":"Partner / Chairman, Saudi Arabia Practice"},{"name":"K\u0026S Talent Partner","value":"K\u0026S Talent Partner"},{"name":"Partner / Chief Human Resources Officer","value":"Partner / Chief Human Resources Officer"},{"name":"Chairman","value":"Chairman"},{"name":"Senior Counsel","value":"Senior Counsel"},{"name":"Associate Director, E-Discovery Operations","value":"Associate Director, E-Discovery Operations"},{"name":"Counsel","value":"Counsel"},{"name":"Senior Associate","value":"Senior Associate"},{"name":"Associate","value":"Associate"},{"name":"Senior Attorney","value":"Senior Attorney"},{"name":"Senior Lawyer","value":"Senior Lawyer"},{"name":"Attorney","value":"Attorney"},{"name":"Senior Counsel and Policy Advisor","value":"Senior Counsel and Policy Advisor"},{"name":"Managing Director - Capital Solutions","value":"Managing Director - Capital Solutions"},{"name":"Senior Government Relations Advisor","value":"Senior Government Relations Advisor"},{"name":"Associate General Counsel","value":"Associate General Counsel"},{"name":"Senior Advisor","value":"Senior Advisor"},{"name":"Patent Agent","value":"Patent Agent"},{"name":"Consultant","value":"Consultant"},{"name":"Government Relations Advisor","value":"Government Relations Advisor"},{"name":"Chief of Lateral Partner Recruiting \u0026 Integration","value":"Chief of Lateral Partner Recruiting \u0026 Integration"},{"name":"Chief Financial Officer","value":"Chief Financial Officer"},{"name":"Chief Information Officer","value":"Chief Information Officer"},{"name":"Chief Revenue Officer","value":"Chief Revenue Officer"},{"name":"Chief Recruiting Officer","value":"Chief Recruiting Officer"},{"name":"Chief Lawyer Talent Development Officer","value":"Chief Lawyer Talent Development Officer"},{"name":"Chief Marketing Officer","value":"Chief Marketing Officer"},{"name":"Tax Consultant","value":"Tax Consultant"},{"name":"Director of Community Affairs","value":"Director of Community Affairs"},{"name":"Director of Facilities \u0026 Admin Operations","value":"Director of Facilities \u0026 Admin Operations"},{"name":"Senior Office Manager","value":"Senior Office Manager"},{"name":"Director of Operations","value":"Director of Operations"},{"name":"Pro Bono Deputy","value":"Pro Bono Deputy"},{"name":"Director of Office Operations","value":"Director of Office Operations"},{"name":"Director of Operations Europe","value":"Director of Operations Europe"},{"name":"Law Clerk","value":"Law Clerk"},{"name":"Deputy General Counsel","value":"Deputy General Counsel"}],"schools":[{"name":"(Commercial Law), in front of Monash University, Australia","value":3045},{"name":"Aberystwyth University","value":3004},{"name":"Albany Law School","value":2118},{"name":"American University Washington College of Law","value":3042},{"name":"American University, Washington College of Law","value":3024},{"name":"Appalachian School of Law","value":2891},{"name":"Ateneo de Manila University","value":2914},{"name":"Ave Maria School of Law","value":2892},{"name":"Baylor University School of Law","value":181},{"name":"Benjamin N. Cardozo School of Law","value":2619},{"name":"Binghamton University","value":3002},{"name":"Boston College Law School","value":245},{"name":"Boston University School of Law","value":247},{"name":"BPP Law School Leeds","value":2642},{"name":"BPP Law School London","value":2782},{"name":"BPP University","value":2984},{"name":"Brooklyn Law School","value":2705},{"name":"Cairo University, Law School","value":2962},{"name":"California Western School of Law","value":315},{"name":"Capital University Law School","value":327},{"name":"Case Western Reserve University School of Law","value":345},{"name":"Cecil C. Humphreys School of Law","value":2235},{"name":"Chapman University School of Law","value":377},{"name":"Charleston School of Law","value":2910},{"name":"City Law School, London","value":2998},{"name":"City Law School","value":2857},{"name":"Clark University","value":3006},{"name":"Cleveland-Marshall College of Law","value":426},{"name":"Columbia University School of International and Public Affairs","value":3008},{"name":"Columbia University School of Law","value":485},{"name":"Columbia University","value":3126},{"name":"Columbus School of Law, Catholic University of America","value":3010},{"name":"Columbus School of Law","value":350},{"name":"Concord Law School of Kaplan University","value":1026},{"name":"Cornell Law School","value":512},{"name":"Creighton University School of Law","value":518},{"name":"Creighton University","value":3025},{"name":"Cumberland School of Law","value":1759},{"name":"CUNY School of Law","value":2893},{"name":"David A. Clarke School of Law","value":2399},{"name":"Deakin University School of Law","value":2907},{"name":"DePaul University College of Law","value":565},{"name":"DePaul University College of Law","value":3060},{"name":"Dickinson School of Law","value":2719},{"name":"Drake University Law School","value":609},{"name":"Duke University School of Law","value":613},{"name":"Duquesne University School of Law","value":614},{"name":"Dwayne O. Andreas School of Law","value":173},{"name":"Edinburgh Law School","value":3160},{"name":"Emory University School of Law","value":659},{"name":"ESADE Business and Law School – Universidad Ramon Llull","value":3215},{"name":"Fachseminare von Fürstenberg","value":2918},{"name":"Faculté Libre de Droit, Université Catholique de Lille","value":3055},{"name":"Faculty of Law, University of Zagreb","value":2983},{"name":"Faculty of Law","value":2944},{"name":"Faculty of Law","value":3039},{"name":"Federal University of Rio de Janeiro","value":3022},{"name":"Federal University of Rio Grande do Sul School of Law (Brazil)","value":3062},{"name":"Florida A\u0026M University College of Law","value":699},{"name":"Florida Coastal School of Law","value":2894},{"name":"Florida International College of Law","value":707},{"name":"Florida State University College of Law","value":720},{"name":"Fordham University School of Law","value":722},{"name":"Franklin Pierce Law Center","value":734},{"name":"Friedrich-Schiller-Universität Jena","value":3015},{"name":"George Mason University School of Law","value":752},{"name":"George Washington University Law School","value":753},{"name":"Georgetown University Law Center","value":755},{"name":"Georgia State University College of Law","value":761},{"name":"Ghent Law School","value":2793},{"name":"Golden Gate University School of Law","value":770},{"name":"Gonzaga University School of Law","value":772},{"name":"Graduate Institute of International and Development Studies, Geneva","value":2997},{"name":"Hamline University School of Law","value":811},{"name":"Harvard Law School","value":824},{"name":"Hebrew University of Jerusalem Faculty of Law","value":2994},{"name":"Hofstra University School of Law","value":858},{"name":"Howard University School of Law","value":872},{"name":"Huazhong University of Science and Technology","value":3016},{"name":"Humboldt University of Berlin","value":3012},{"name":"Indiana University School of Law","value":2711},{"name":"Indiana University School of Law","value":890},{"name":"International Association of Privacy Professionals","value":3009},{"name":"J. Reuben Clark Law School","value":262},{"name":"Jacob D. Fuchsberg Law Center","value":2084},{"name":"James Cook University of North Queensland","value":3034},{"name":"Jean Moulin University Lyon 3, France","value":2938},{"name":"Johns Hopkins Bloomberg School of Public Health","value":2992},{"name":"Justus-Liebig-Universität Gießen Rechtswissenschaft (Germany)","value":3063},{"name":"Kansas City School of Law","value":2247},{"name":"Keio University","value":2968},{"name":"Kent College of Law","value":883},{"name":"Kline School of Law","value":611},{"name":"KU Leuven","value":3007},{"name":"Levin College of Law","value":2189},{"name":"Lewis and Clark Law School","value":1089},{"name":"Liberty University School of Law","value":1094},{"name":"Lincoln College of Law","value":2253},{"name":"LL.M. in International Crime and Justice UNICRI","value":2937},{"name":"Loyola Law School","value":2895},{"name":"Loyola University Chicago School of Law","value":1135},{"name":"Loyola University New Orleans College of Law","value":1136},{"name":"Marquette University Law School","value":1176},{"name":"McGeorge School of Law","value":2402},{"name":"McGill University","value":2659},{"name":"Melbourne Law School","value":2899},{"name":"Mercer University Walter F. George School of Law","value":1221},{"name":"Mexico Autonomous Institute of Technology","value":2996},{"name":"Michael E. Moritz College of Law","value":2728},{"name":"Michigan State University College of Law","value":1245},{"name":"Mississippi College School of Law","value":1285},{"name":"Moscow State University","value":2815},{"name":"National and Kapodistrian University of Athens","value":3032},{"name":"National Law University Jodhpur","value":3020},{"name":"National University of Singapore, Faculty of Law","value":2662},{"name":"New England School of Law","value":2886},{"name":"New York Law School","value":1403},{"name":"New York University School of Law","value":1406},{"name":"Norman Adrian Wiggins School of Law","value":323},{"name":"North Carolina Central University School of Law","value":1417},{"name":"Northeastern University School of Law","value":1430},{"name":"Northern Illinois University College of Law","value":1432},{"name":"Northwestern Pritzker School of Law","value":1451},{"name":"Notre Dame Law School","value":2278},{"name":"Ohio Northern University Law School","value":3036},{"name":"Oklahoma City University School of Law","value":1487},{"name":"Osgoode Hall Law School","value":3124},{"name":"Pace University School of Law","value":1516},{"name":"Panteion University","value":3033},{"name":"Paul M. Hebert Law Center","value":2713},{"name":"Pennsylvania State University, Dickinson School of Law","value":1562},{"name":"Pepperdine University School of Law","value":1570},{"name":"Pettit College of Law","value":1473},{"name":"Pontificia Universidad Catolica de Chile","value":3203},{"name":"Pontificia Universidad Catolica del Peru","value":3011},{"name":"Pontificia Universidad Javeriana","value":3013},{"name":"Pontificia Universidade Catolica de Sao Paulo","value":3095},{"name":"Prince Sultan University College of Law","value":3167},{"name":"Queens College, Cambridge","value":3003},{"name":"Quinnipiac University School of Law","value":1626},{"name":"Ralph R. Papitto School of Law","value":1686},{"name":"Regent University School of Law","value":1649},{"name":"Rice University","value":3043},{"name":"Ruprecht-Karls-Universität Heidelberg","value":3049},{"name":"Rutgers University School of Law-Newark","value":1699},{"name":"Rutgers University School of Law","value":1697},{"name":"S.J. Quinney College of Law","value":2408},{"name":"Saint Louis University School of Law","value":1732},{"name":"Salmon P. Chase College of Law","value":1433},{"name":"Sandra Day O'Connor College of Law","value":103},{"name":"Santa Clara University School of Law","value":1771},{"name":"Seattle University School of Law","value":1787},{"name":"Seton Hall University School of Law","value":1790},{"name":"Shepard Broad Law Center","value":1460},{"name":"South Texas College of Law","value":2721},{"name":"Southern Illinois University School of Law","value":1849},{"name":"Southern Methodist University Dedman School of Law","value":1852},{"name":"Southern University Law Center","value":1857},{"name":"Southwestern Law School","value":1876},{"name":"St. John's University School of Law","value":2724},{"name":"St. Mary's University School of Law","value":1896},{"name":"St. Thomas University School of Law","value":1746},{"name":"Stanford Law School","value":1904},{"name":"Stetson University College of Law","value":1910},{"name":"Sturm College of Law","value":2184},{"name":"Suffolk University Law School","value":1921},{"name":"Syracuse University College of Law","value":1956},{"name":"Temple University Beasley School of Law","value":1974},{"name":"Texas A\u0026M School of Law","value":1980},{"name":"Texas Tech University School of Law","value":1994},{"name":"Texas Wesleyan University School of Law","value":1996},{"name":"The College of Law Australia","value":3091},{"name":"The College of Law, London","value":2935},{"name":"The John Marshall Law School","value":2034},{"name":"The Judge Advocate General's Legal Center and School","value":2896},{"name":"The Ohio State University Moritz College of Law","value":2990},{"name":"The University of Akron School of Law","value":2143},{"name":"The University of Alabama School of Law","value":2045},{"name":"The University of Birmingham, U.K.","value":2796},{"name":"The University of Iowa College of Law","value":2206},{"name":"The University of Texas School of Law","value":2055},{"name":"The University of Tulsa College of Law","value":2407},{"name":"Thomas Jefferson School of Law","value":685},{"name":"Thomas M. Cooley Law School","value":2729},{"name":"Thurgood Marshall School of Law","value":1992},{"name":"Tianjin University of Commerce","value":2995},{"name":"Tulane University Law School","value":2113},{"name":"UC Davis School of Law","value":2160},{"name":"UCLA School of Law","value":2162},{"name":"Universidad Católica de Honduras","value":2916},{"name":"Universidad Francisco Marroquin","value":3090},{"name":"Universidad Panamericana","value":2904},{"name":"Universidad Torcuato di Tella","value":3035},{"name":"Universidade de São Paulo, Faculdade de Direito","value":3028},{"name":"Universidade Presbiteriana Mackenzie","value":2977},{"name":"Università Commerciale Luigi Bocconi","value":3135},{"name":"University at Buffalo Law School","value":1928},{"name":"University College Dublin Law School","value":2900},{"name":"University of Alberta Faculty of Law","value":3088},{"name":"University of Amsterdam","value":2980},{"name":"University of Arizona, James E. Rogers College of Law","value":2149},{"name":"University of Arkansas School of Law","value":2154},{"name":"University of Baltimore School of Law","value":2156},{"name":"University of California College of the Law","value":3196},{"name":"University of California Hastings College of Law","value":2158},{"name":"University of California Irvine School of Law","value":2161},{"name":"University of California, Berkeley, School of Law","value":2159},{"name":"University of California, Davis","value":3019},{"name":"University of Cambridge, U.K","value":2991},{"name":"University of Canterbury","value":2981},{"name":"University of Central Florida","value":3027},{"name":"University of Chester Law School","value":3005},{"name":"University of Chicago Law School","value":2174},{"name":"University of Chicago","value":3038},{"name":"University of Cincinnati College of Law","value":2175},{"name":"University of Colorado School of Law","value":2177},{"name":"University of Connecticut School of Law","value":2180},{"name":"University of Dayton School of Law","value":2182},{"name":"University of Detroit Mercy School of Law","value":2185},{"name":"University of East Anglia","value":3000},{"name":"University of Florida, Levin College of Law","value":3188},{"name":"University of Georgia School of Law","value":2190},{"name":"University of Houston Law Center","value":2197},{"name":"University of Hull","value":3040},{"name":"University of Idaho College of Law","value":2201},{"name":"University of Illinois College of Law","value":2204},{"name":"University of Kansas School of Law","value":2208},{"name":"University of Kentucky College of Law","value":2210},{"name":"University of La Verne College of Law","value":2211},{"name":"University of Law, London","value":2999},{"name":"University of Lethbridge","value":3030},{"name":"University of Louisville Brandeis School of Law","value":2214},{"name":"University of Maine School of Law","value":2391},{"name":"University of Maryland School of Law","value":2224},{"name":"University of Miami School of Law","value":2236},{"name":"University of Michigan Law School","value":2237},{"name":"University of Minnesota Law School","value":2243},{"name":"University of Mississippi School of Law","value":2244},{"name":"University of Missouri School of Law","value":2246},{"name":"University of Montana School of Law","value":2048},{"name":"University of Nebraska College of Law","value":2744},{"name":"University of New Mexico School of Law","value":2262},{"name":"University of North Carolina School of Law","value":2266},{"name":"University of North Dakota School of Law","value":2271},{"name":"University of Oklahoma Law Center","value":2747},{"name":"University of Oregon School of Law","value":2281},{"name":"University of Pennsylvania Law School","value":2282},{"name":"University of Pittsburgh School of Law","value":2354},{"name":"University of Richmond School of Law","value":2370},{"name":"University of San Diego School of Law","value":2377},{"name":"University of San Francisco School of Law","value":2378},{"name":"University of South Carolina School of Law","value":2750},{"name":"University of South Dakota School of Law","value":2387},{"name":"University of Southern California Gould School of Law","value":3051},{"name":"University of St. Thomas School of Law","value":2751},{"name":"University of Sydney Law School","value":3031},{"name":"University of Tennessee College of Law","value":2051},{"name":"University of the West of England, Bristol","value":3001},{"name":"University of Toledo College of Law","value":2406},{"name":"University of Toronto","value":2912},{"name":"University of Utah","value":3026},{"name":"University of Virginia School of Law","value":2410},{"name":"University of Washington School of Law","value":2412},{"name":"University of Wisconsin Law School","value":2419},{"name":"University of Wyoming College of Law","value":2429},{"name":"University of Zürich","value":3037},{"name":"University Paris Dauphine","value":2976},{"name":"University Paris II Assas","value":2975},{"name":"University Paris II Assas","value":3052},{"name":"USC Gould School of Law","value":2389},{"name":"Utrecht University","value":3085},{"name":"Valparaiso University School of Law","value":2441},{"name":"Vanderbilt University School of Law","value":2442},{"name":"Vermont Law School","value":2451},{"name":"Villanova University School of Law","value":2454},{"name":"Wake Forest University School of Law","value":2471},{"name":"Washburn University School of Law","value":2482},{"name":"Washington and Lee University School of Law","value":2484},{"name":"Washington College of Law","value":61},{"name":"Washington University in St. Louis School of Law","value":2489},{"name":"Wayne State University Law School","value":2493},{"name":"West Virginia University College of Law","value":2517},{"name":"Western New England College School of Law","value":2528},{"name":"Western State College of Law","value":2897},{"name":"Wharton School of Business","value":3044},{"name":"Whittier Law School","value":2564},{"name":"Widener University Delaware Law School","value":2569},{"name":"Willamette University College of Law","value":2573},{"name":"William \u0026 Mary Law School","value":462},{"name":"William H. Bowen School of Law","value":2150},{"name":"William Mitchell College of Law","value":2758},{"name":"William S. Boyd School of Law","value":2256},{"name":"William S. Richardson School of Law","value":2195},{"name":"Wilmington University","value":2993},{"name":"Yale Law School","value":2605}],"offices":[{"name":"Abu Dhabi","value":13},{"name":"Atlanta","value":1},{"name":"Austin","value":12},{"name":"Brussels","value":23},{"name":"Charlotte","value":8},{"name":"Chicago","value":21},{"name":"Dallas","value":28},{"name":"Denver","value":22},{"name":"Dubai","value":6},{"name":"Frankfurt","value":9},{"name":"Geneva","value":15},{"name":"Houston","value":4},{"name":"London","value":5},{"name":"Los Angeles","value":19},{"name":"Miami","value":25},{"name":"New York","value":3},{"name":"Northern Virginia","value":24},{"name":"Paris","value":14},{"name":"Riyadh","value":27},{"name":"Sacramento","value":20},{"name":"San Francisco","value":10},{"name":"Silicon Valley","value":11},{"name":"Singapore","value":16},{"name":"Sydney","value":26},{"name":"Tokyo","value":18},{"name":"Washington, D.C.","value":2}],"capabilities":[{"name":"Corporate, Finance and Investments","value":"cg-1"},{"name":null,"value":72},{"name":null,"value":26},{"name":null,"value":40},{"name":null,"value":27},{"name":null,"value":80},{"name":null,"value":28},{"name":null,"value":35},{"name":null,"value":10},{"name":null,"value":134},{"name":null,"value":121},{"name":null,"value":78},{"name":null,"value":29},{"name":null,"value":32},{"name":null,"value":31},{"name":null,"value":33},{"name":null,"value":126},{"name":"Real Estate","value":36},{"name":null,"value":82},{"name":null,"value":37},{"name":null,"value":115},{"name":"Government Matters","value":"cg-2"},{"name":null,"value":1},{"name":null,"value":6},{"name":null,"value":71},{"name":null,"value":21},{"name":null,"value":23},{"name":null,"value":116},{"name":null,"value":24},{"name":null,"value":135},{"name":null,"value":25},{"name":null,"value":110},{"name":null,"value":20},{"name":null,"value":11},{"name":"Trial and Global Disputes","value":"cg-3"},{"name":null,"value":129},{"name":null,"value":2},{"name":null,"value":38},{"name":null,"value":3},{"name":null,"value":5},{"name":null,"value":19},{"name":null,"value":7},{"name":null,"value":4},{"name":null,"value":136},{"name":null,"value":13},{"name":null,"value":14},{"name":null,"value":15},{"name":null,"value":17},{"name":null,"value":18},{"name":null,"value":16},{"name":"Industries / Issues","value":"cg-4"},{"name":null,"value":133},{"name":null,"value":106},{"name":null,"value":124},{"name":null,"value":111},{"name":null,"value":132},{"name":null,"value":131},{"name":null,"value":102},{"name":null,"value":125},{"name":null,"value":127},{"name":null,"value":107},{"name":null,"value":112},{"name":null,"value":105},{"name":null,"value":109},{"name":null,"value":103},{"name":null,"value":128},{"name":null,"value":123},{"name":null,"value":118}]},"title_id":null,"school_id":null,"office_id":null,"capability_id":"24","extra_filter_id":null,"extra_filter_type":null,"q":null,"starts_with":"R","per_page":12,"people":[{"id":445247,"version":1,"owner_type":"Person","owner_id":7299,"payload":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children\u0026rsquo;s, psychiatric, and rural hospitals along with healthcare provider associations.\u003c/p\u003e\n\u003cp\u003eAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\u003c/p\u003e\n\u003cp\u003eRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\u003c/p\u003e\n\u003cp\u003eWhen away from the office, Renee enjoys spending time with family and attending concerts.\u003c/p\u003e\n\u003cp\u003eRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean\u0026rsquo;s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship.\u003c/p\u003e","slug":"renee-rayne","email":"rrayne@kslaw.com","phone":null,"matters":["\u003cp\u003eAssisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.\u003c/p\u003e","\u003cp\u003eStructuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals\u0026rsquo; uncompensated costs of treating uninsured patients.\u003c/p\u003e","\u003cp\u003eDrafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.\u003c/p\u003e","\u003cp\u003eResearching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.\u003c/p\u003e","\u003cp\u003eNegotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.\u003c/p\u003e","\u003cp\u003eAdvising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.\u003c/p\u003e","\u003cp\u003eAssisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":740,"guid":"740.smart_tags","index":3,"source":"smartTags"},{"id":826,"guid":"826.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Rayne","nick_name":"Renee","clerkships":[],"first_name":"Renee","title_rank":9999,"updated_by":34,"law_schools":[{"id":2055,"meta":{"degree":"J.D.","honors":"with honors","is_law_school":"1","graduation_date":"2014-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":" ","name_suffix":"","recognitions":[{"title":"“Ones to Watch in America,” Healthcare Law","detail":"Best Lawyers, 2022-2026"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eA partner in the firm\u0026rsquo;s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children\u0026rsquo;s, psychiatric, and rural hospitals along with healthcare provider associations.\u003c/p\u003e\n\u003cp\u003eAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\u003c/p\u003e\n\u003cp\u003eRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\u003c/p\u003e\n\u003cp\u003eWhen away from the office, Renee enjoys spending time with family and attending concerts.\u003c/p\u003e\n\u003cp\u003eRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean\u0026rsquo;s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship.\u003c/p\u003e","matters":["\u003cp\u003eAssisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.\u003c/p\u003e","\u003cp\u003eStructuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals\u0026rsquo; uncompensated costs of treating uninsured patients.\u003c/p\u003e","\u003cp\u003eDrafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.\u003c/p\u003e","\u003cp\u003eResearching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.\u003c/p\u003e","\u003cp\u003eNegotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.\u003c/p\u003e","\u003cp\u003eAdvising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.\u003c/p\u003e","\u003cp\u003eAssisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.\u003c/p\u003e"],"recognitions":[{"title":"“Ones to Watch in America,” Healthcare Law","detail":"Best Lawyers, 2022-2026"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":13321}]},"capability_group_id":2},"created_at":"2026-01-26T14:39:50.000Z","updated_at":"2026-01-26T14:39:50.000Z","searchable_text":"Rayne{{ FIELD }}{:title=\u0026gt;\"“Ones to Watch in America,” Healthcare Law\", :detail=\u0026gt;\"Best Lawyers, 2022-2026\"}{{ FIELD }}Assisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval.{{ FIELD }}Structuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals’ uncompensated costs of treating uninsured patients.{{ FIELD }}Drafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals.{{ FIELD }}Researching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board.{{ FIELD }}Negotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program.{{ FIELD }}Advising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs.{{ FIELD }}Assisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.{{ FIELD }}A partner in the firm’s Healthcare practice, Renee Rayne represents public hospitals, private hospitals and physician groups in regulatory compliance and transactional matters, particularly related to participation in federal and state reimbursement programs. Approaching each transaction with an analytical eye, Renee identifies issues and risk tolerance to help clients solve problems and reach their goals.\nRenee advises hospital systems across a wide-range of regulatory compliance and reimbursement matter, including compliance with the Stark Law, federal and state anti-kickback statutes, HIPAA, compliance issues related to participation in Medicaid and Medicare programs, regulatory audits and appeals, along with other related regulatory requirements. She has significant experience representing public, investor-owned, non-profit, children’s, psychiatric, and rural hospitals along with healthcare provider associations.\nAdditionally, Renee has assisted in the development, implementation, and operation of new Medicaid reimbursement programs in several states, including managed care directed payment programs and Upper Payment Limit (UPL) programs. She analyzes hospital data to model the reimbursement impacts of federal and state policy changes, as well as operational modifications within hospital systems.\nRenee takes a collaborative approach to matters, strategically partnering with clients to navigate complex negotiations. Her advocacy includes working with state regulatory agencies and facilitating coalitions of industry stakeholders to advocate to state and federal lawmakers for improved reimbursement opportunities.\nWhen away from the office, Renee enjoys spending time with family and attending concerts.\nRenee earned her J.D. from the University of Texas School of Law and her B.A. from Vanderbilt University. Renee interned with the Honorable E. Clifton Knowles, Magistrate Judge of the U.S. District Court for the Middle District of Tennessee, and was a recipient of the Dean’s Achievement Award for Academic Excellence and William Ellis Woods Endowed Presidential Scholarship. Partner “Ones to Watch in America,” Healthcare Law Best Lawyers, 2022-2026 Vanderbilt University Vanderbilt University School of Law The University of Texas at Austin The University of Texas School of Law Tennessee Texas Texas State Bar American Health Lawyers Association Assisting hospitals and state Medicaid agencies in designing state-directed Medicaid managed care payment programs and assisting in responses to CMS inquiries in order to obtain program approval. Structuring, developing and assisting hospitals in working with healthcare industry associations, including the Tennessee Hospital Association, to implement a program to address hospitals’ uncompensated costs of treating uninsured patients. Drafting healthcare provider contracts between hospitals, physicians and other healthcare organizations and professionals. Researching and drafting briefing materials for hospital intervenors in a disallowance appeal before the Department of Health and Human Services Departmental Appeals Board. Negotiating agreements with Medicaid managed care organizations to effectuate hospital participation in a state-directed Medicaid managed care payment program. Advising Texas hospitals related to their participation in the 1115 Medicaid Transformation Waiver and its associated Uncompensated Care and Delivery System Reform Incentive Payment programs. Assisting hospitals in obtaining Medicaid managed care incentive payments for developing and implementing initiatives to improve access and quality of care to Medicaid managed care beneficiaries.","searchable_name":"Renee Rayne","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":34,"capability_group_featured":null,"home_page_featured":null},{"id":442370,"version":1,"owner_type":"Person","owner_id":880,"payload":{"bio":"\u003cp\u003eJohn Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by\u0026nbsp;President George W. Bush\u0026nbsp;and confirmed by unanimous consent of the U.S. Senate.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;has named\u0026nbsp;John \"White-Collar MVP of the Year\".\u0026nbsp; He also has been\u0026nbsp;recognized as one of the top 100 trial lawyers in America by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;and as a Life Sciences Star for litigation by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e.\u0026nbsp; Most recently, he was elected President of the National Association of Former United States Attorneys.\u003c/p\u003e\n\u003cp\u003eDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President\u0026rsquo;s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\u003c/p\u003e\n\u003cp\u003eAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services\u0026rsquo; Inspector General\u0026rsquo;s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General\u0026rsquo;s Advisory Committee on Sentencing, and as a member of the Attorney General\u0026rsquo;s Advisory Committee on White Collar Crime.\u003c/p\u003e\n\u003cp\u003eJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\u003c/p\u003e\n\u003cp\u003eIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys\u0026rsquo; Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general\u0026rsquo;s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;whistleblower litigation.\u003c/p\u003e\n\u003cp\u003eIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc.,\u0026nbsp;where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;cases.\u003c/p\u003e","slug":"john-richter","email":"jrichter@kslaw.com","phone":null,"matters":["\u003cp\u003eSuccessful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.\u003c/p\u003e","\u003cp\u003eSuccessful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ civil investigation and dismissal of a whistleblower\u0026rsquo;s complaint of publicly traded health insurer based on false claims allegations.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eSuccessful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.\u003c/p\u003e","\u003cp\u003eInvestigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company\u0026rsquo;s computer system and theft of trade secret and proprietary information.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[{"id":3134}]},"expertise":[{"id":6,"guid":"6.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":4,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":5,"source":"capabilities"},{"id":20,"guid":"20.capabilities","index":6,"source":"capabilities"},{"id":750,"guid":"750.smart_tags","index":7,"source":"smartTags"},{"id":1303,"guid":"1303.smart_tags","index":8,"source":"smartTags"},{"id":766,"guid":"766.smart_tags","index":9,"source":"smartTags"},{"id":780,"guid":"780.smart_tags","index":10,"source":"smartTags"},{"id":11,"guid":"11.capabilities","index":11,"source":"capabilities"},{"id":952,"guid":"952.smart_tags","index":12,"source":"smartTags"},{"id":984,"guid":"984.smart_tags","index":13,"source":"smartTags"},{"id":1188,"guid":"1188.smart_tags","index":14,"source":"smartTags"},{"id":1199,"guid":"1199.smart_tags","index":15,"source":"smartTags"},{"id":1248,"guid":"1248.smart_tags","index":16,"source":"smartTags"}],"is_active":true,"last_name":"Richter","nick_name":"John","clerkships":[{"name":"Law Clerk, J. Owen Forrester, U.S. District Court for the Northern District of Georgia","years_held":"1992-1994"}],"first_name":"John","title_rank":9999,"updated_by":202,"law_schools":[{"id":2410,"meta":{"degree":"J.D.","honors":null,"is_law_school":1,"graduation_date":"1992-01-01 00:00:00 UTC"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"C.","name_suffix":"","recognitions":[{"title":"“Richter stands out for his significant capabilities as a trial lawyer”","detail":"Legal 500 - 2024"},{"title":"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)","detail":"NAFUSA 2023"},{"title":"Selected,Top 100 Trial Lawyers","detail":"Benchmark Litigation, 2017"},{"title":"Selected, Life Sciences Star","detail":"LMG Life Sciences, 2017"},{"title":"Selected, White Collar Defense MVP","detail":"Law360, 2016"},{"title":"Elected to the Board of Directors, 2017","detail":"National Association of Former United States Attorneys"}],"linked_in_url":null,"seodescription":"John Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group. Find out more about him.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eJohn Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by\u0026nbsp;President George W. Bush\u0026nbsp;and confirmed by unanimous consent of the U.S. Senate.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;has named\u0026nbsp;John \"White-Collar MVP of the Year\".\u0026nbsp; He also has been\u0026nbsp;recognized as one of the top 100 trial lawyers in America by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;and as a Life Sciences Star for litigation by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e.\u0026nbsp; Most recently, he was elected President of the National Association of Former United States Attorneys.\u003c/p\u003e\n\u003cp\u003eDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President\u0026rsquo;s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\u003c/p\u003e\n\u003cp\u003eAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services\u0026rsquo; Inspector General\u0026rsquo;s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General\u0026rsquo;s Advisory Committee on Sentencing, and as a member of the Attorney General\u0026rsquo;s Advisory Committee on White Collar Crime.\u003c/p\u003e\n\u003cp\u003eJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\u003c/p\u003e\n\u003cp\u003eIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys\u0026rsquo; Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general\u0026rsquo;s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;whistleblower litigation.\u003c/p\u003e\n\u003cp\u003eIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc.,\u0026nbsp;where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;cases.\u003c/p\u003e","matters":["\u003cp\u003eSuccessful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.\u003c/p\u003e","\u003cp\u003eSuccessful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.\u003c/p\u003e","\u003cp\u003eRepresentation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eSuccessful declination of DOJ civil investigation and dismissal of a whistleblower\u0026rsquo;s complaint of publicly traded health insurer based on false claims allegations.\u003c/p\u003e","\u003cp\u003eSuccessful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.\u003c/p\u003e","\u003cp\u003eSuccessful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.\u003c/p\u003e","\u003cp\u003eIndependent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.\u003c/p\u003e","\u003cp\u003eInvestigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company\u0026rsquo;s computer system and theft of trade secret and proprietary information.\u003c/p\u003e"],"recognitions":[{"title":"“Richter stands out for his significant capabilities as a trial lawyer”","detail":"Legal 500 - 2024"},{"title":"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)","detail":"NAFUSA 2023"},{"title":"Selected,Top 100 Trial Lawyers","detail":"Benchmark Litigation, 2017"},{"title":"Selected, Life Sciences Star","detail":"LMG Life Sciences, 2017"},{"title":"Selected, White Collar Defense MVP","detail":"Law360, 2016"},{"title":"Elected to the Board of Directors, 2017","detail":"National Association of Former United States Attorneys"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":4491}]},"capability_group_id":2},"created_at":"2025-11-05T05:03:40.000Z","updated_at":"2025-11-05T05:03:40.000Z","searchable_text":"Richter{{ FIELD }}{:title=\u0026gt;\"“Richter stands out for his significant capabilities as a trial lawyer”\", :detail=\u0026gt;\"Legal 500 - 2024\"}{{ FIELD }}{:title=\u0026gt;\"Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024)\", :detail=\u0026gt;\"NAFUSA 2023\"}{{ FIELD }}{:title=\u0026gt;\"Selected,Top 100 Trial Lawyers\", :detail=\u0026gt;\"Benchmark Litigation, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Selected, Life Sciences Star\", :detail=\u0026gt;\"LMG Life Sciences, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Selected, White Collar Defense MVP\", :detail=\u0026gt;\"Law360, 2016\"}{{ FIELD }}{:title=\u0026gt;\"Elected to the Board of Directors, 2017\", :detail=\u0026gt;\"National Association of Former United States Attorneys\"}{{ FIELD }}Successful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges.{{ FIELD }}Successful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government.{{ FIELD }}Independent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management.{{ FIELD }}Successful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts.{{ FIELD }}Representation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company.{{ FIELD }}Representation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation.{{ FIELD }}Successful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act.{{ FIELD }}Successful declination of DOJ civil investigation and dismissal of a whistleblower’s complaint of publicly traded health insurer based on false claims allegations.{{ FIELD }}Successful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts.{{ FIELD }}Successful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act.{{ FIELD }}Independent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities.{{ FIELD }}Investigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company’s computer system and theft of trade secret and proprietary information.{{ FIELD }}John Richter is a trial and investigations partner in the Special Matters and Investigations Practice Group, and represents and defends companies, Boards of Directors, Board committees, and individuals facing a variety of white-collar criminal and regulatory enforcement matters, parallel civil litigation, and internal corporate investigations. John previously served as the Acting Assistant Attorney General in charge of the Criminal Division at the U.S. Department of Justice and as the U.S. Attorney for the Western District of Oklahoma, having been nominated by President George W. Bush and confirmed by unanimous consent of the U.S. Senate. \nLaw360 has named John \"White-Collar MVP of the Year\".  He also has been recognized as one of the top 100 trial lawyers in America by Benchmark Litigation and as a Life Sciences Star for litigation by LMG Life Sciences.  Most recently, he was elected President of the National Association of Former United States Attorneys.\nDuring his tenure at the Criminal Division, he led investigations, prosecutions, and policy development in many areas of federal criminal law, including healthcare fraud, securities fraud, Foreign Corrupt Practices Act and export violations, bank secrecy and money laundering offenses, public corruption, and organized crime. He served as a member of the President’s Corporate Fraud Task Force and oversaw the Enron Task Force. He also served as the Commissioner Ex-Officio to the U.S. Sentencing Commission and represented the Department in matters before the Committee on Foreign Investment in the U.S.\nAs U.S. Attorney, John served as the chief federal law enforcement officer for the district, tried cases, argued appeals, and oversaw the prosecution and defense of a wide-range of criminal and civil matters on behalf of the U.S., including bank fraud, healthcare fraud, money laundering and other economic and regulatory cases. In 2009, he was awarded the U.S. Department of Health and Human Services’ Inspector General’s Award for Combating Medicare and Medicaid Fraud. He also served as Chairman of the Attorney General’s Advisory Committee on Sentencing, and as a member of the Attorney General’s Advisory Committee on White Collar Crime.\nJohn began his career as a federal prosecutor as an Assistant U.S. Attorney in Atlanta and Oklahoma City, during which time he investigated and prosecuted a wide-range of federal cases, including health care, bank, and securities fraud. He began his career as a prosecutor as an Assistant District Attorney in Cobb County, Georgia.\nIn private practice, John has represented and defended clients in trials and investigations involving U.S. Attorneys’ Offices in over fifteen different districts around the country, the Criminal and Civil Divisions at the Justice Department, and state attorney general’s offices for all 50 states and the District of Columbia. These matters often have also involved parallel proceedings by regulatory agencies and parallel class action or qui tam whistleblower litigation.\nIn addition to tenures as prosecutor and in private practice, John also served as Vice President and Deputy General Counsel at WellCare Health Plans, Inc., where he led the successful resolution of enterprise-threatening criminal and civil investigations by the U.S. Department of Justice, as well as parallel investigations by other federal and state regulatory agencies, private securities class actions, derivative class actions, and qui tam cases. john richter Partner “Richter stands out for his significant capabilities as a trial lawyer” Legal 500 - 2024 Elected, President – National Association of Former United States Attorneys (NAFUSA) (2023-2024) NAFUSA 2023 Selected,Top 100 Trial Lawyers Benchmark Litigation, 2017 Selected, Life Sciences Star LMG Life Sciences, 2017 Selected, White Collar Defense MVP Law360, 2016 Elected to the Board of Directors, 2017 National Association of Former United States Attorneys Emory University Emory University School of Law University of Virginia University of Virginia School of Law Supreme Court of the United States U.S. Court of Appeals for the Fourth Circuit U.S. Court of Appeals for the Tenth Circuit U.S. Court of Appeals for the Eleventh Circuit U.S. District Court for the Western District of Oklahoma U.S. District Court for the Northern District of Georgia District of Columbia Georgia Oklahoma President, National Association of Former United States Attorneys Law Clerk, J. Owen Forrester, U.S. District Court for the Northern District of Georgia Successful defense and full jury acquittal on all charges of Vascular Solutions, Inc., a publicly traded medical device company, in a high-stakes criminal trial in the W.D. Tex., stemming from alleged conspiracy and off-label marketing charges. Successful dismissal of multi-billion dollar whistleblower lawsuit in the N.D. Cal.,against global telecommunications provider on claims of fraud in connections with wireless services provided to departments and agencies of the federal government. Independent internal investigation on behalf of independent members of the Board of a publicly traded real estate investment trust company into certain financial transactions and activities by management. Successful negotiation and resolution of enterprise-threatening investigations by DOJ and attorneys general for all 50 states and the District of Columbia against a global medical device manufacturer based on allegations of kickbacks and violations of federal and state false claims acts. Representation of and successful declination against senior executives of a global pharmaceutical company in DOJ FCPA investigation of the company. Representation of and successful declination against former Prime Minister of European country in DOJ FCPA investigation. Successful declination of DOJ criminal and civil investigation of a publicly traded global medical device company based on allegations of off-label marketing and violations of the federal false claims act. Successful declination of DOJ civil investigation and dismissal of a whistleblower’s complaint of publicly traded health insurer based on false claims allegations. Successful negotiation and resolution of civil investigations by DOJ and 47 state attorneys general against a publicly traded pharmacy service provider based on allegations of violations of federal and state false claims acts. Successful declinations of numerous DOJ civil investigations against a drug monitoring and testing company based on various allegations of violations of the federal false claims act. Independent internal investigation on behalf of the Board of a publicly traded healthcare intermediary service provider into alleged financial and accounting irregularities. Investigation of and referral to law enforcement for the successful criminal prosecution of a former employee of a global oil and gas services company based on the unlawful intrusion into the company’s computer system and theft of trade secret and proprietary information.","searchable_name":"John C. Richter","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":426313,"version":1,"owner_type":"Person","owner_id":2422,"payload":{"bio":"\u003cp\u003eAdam Robison focuses on a wide range of matters involving healthcare providers and suppliers. A partner in our Healthcare practice, Adam represents healthcare clients in a variety of regulatory and transactional matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAdam represents public and private hospital systems, academic medical centers, medical schools, children's hospitals, hospices, laboratories, physicians and suppliers in various regulatory and transactional matters.\u003c/p\u003e\n\u003cp\u003eAdam counsels clients concerning False Claims Act and Civil Monetary Penalty investigations, fraud and abuse, along with anti-kickback and physician self-referral issues, including physician contracting. He has also worked with clients on Medicare and Medicaid administrative overpayment appeals; Medicare and Medicaid self-disclosures; and compliance with the 60-day overpayment rule; as well as on Medicaid supplemental payment and 1115 Waiver programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Adam advises clients on a variety of transactional matters, including hospital joint operating company agreements, merger and acquisition agreements, and academic affiliation agreements.\u003c/p\u003e","slug":"adam-robison","email":"arobison@kslaw.com","phone":"+1-832-714-8015","matters":["\u003cp\u003eLitigation/Administrative Appeals\u003cbr /\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea large healthcare company\u003c/strong\u003e in obtaining an $18 million arbitration award against the sellers of a hospice pursuant to claims for indemnification and fraud related to a self-disclosure audit that Adam also facilitated.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea drug testing laboratory\u003c/strong\u003e in reducing a $31 million Medicare overpayment resulting in more than a $29 million overpayment reduction.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ean oncologist\u003c/strong\u003e before the Administrative Law Judge in a Medicare overpayment case resulting in the full reversal of the alleged multimillion-dollar overpayment.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of children\u0026rsquo;s hospitals\u003c/strong\u003e in connection with dispute involving cost-settling certain Medicaid primary care case management payments resulting in multimillion-dollar settlements.\u003c/p\u003e","\u003cp\u003eNegotiated a $6 million settlement agreement for \u003cstrong data-redactor-tag=\"strong\"\u003ea children\u0026rsquo;s hospital\u003c/strong\u003e in connection with a dispute involving cost-settling certain Medicaid primary care case management payments.\u003c/p\u003e","\u003cp\u003eFalse Claims Act Matters and Settlements\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea county-owned hospital\u003c/strong\u003e in an approximate $21.75 million settlement of a federal False Claims Act \u003cem data-redactor-tag=\"em\"\u003equi tam\u003c/em\u003e lawsuit involving allegations of Stark Law and Anti-Kickback Statute violations without a Corporate Integrity Agreement.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea nursing home chain\u003c/strong\u003e in a $4 million settlement of federal and state False Claims Act lawsuit and negotiation of a Corporate Integrity Agreement related to ambulance arrangement allegations.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea hospital district\u003c/strong\u003e in a favorable $3.3 million settlement of federal and state False Claims Act lawsuit involving physician billing without a Corporate Integrity Agreement.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea national hospice\u003c/strong\u003e in negotiating an approximate $25 million settlement and negotiated Corporate Integrity Agreement based on allegations of lack of medically necessary services.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea county hospital district\u003c/strong\u003e in negotiating an approximate $15 million settlement and negotiated corporate compliance agreement related to allegations of lack of Medicare Secondary Payer issues and claims for prisoners.\u003c/p\u003e","\u003cp\u003eTransactions\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea medical school\u003c/strong\u003e in negotiating $100 plus million joint operating company and physician clinically integrated network agreements.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea medical school\u003c/strong\u003e in the annual negotiation of $220 plus million physician coverage and academic affiliation agreements.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state university/academic medical center\u003c/strong\u003e in the successful negotiation of a $338 million agreement with the state\u0026rsquo;s department of criminal justice for the provision of correctional healthcare services to state inmates.\u003c/p\u003e","\u003cp\u003eHealth Regulatory and Self-Disclosures\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state medical school\u003c/strong\u003e in obtaining provider-based on-campus designation for its $66 million radiation oncology facility resulting in millions of dollars of additional reimbursement per year.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state medical school\u003c/strong\u003e in obtaining a favorable advisory opinion from the Office of Inspector General related to the medical school\u0026rsquo;s prenatal care programs.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ean academic medical center hospital\u003c/strong\u003e in obtaining retroactive listing as a covered entity under the 340B drug discount program, resulting in $4.5 plus million in drug savings.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003emultiple hospital systems and providers\u003c/strong\u003e in self-disclosing overpayments to Medicare Administrative Contractors, the Office of Inspector General (self-disclosure protocol) and various state Medicaid agencies.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003evarious participants\u003c/strong\u003e regarding the development and implementation of Medicaid supplemental payment/1115 Waiver programs to provide enhanced Medicaid payments to hospitals and other providers located in multiple counties in Texas.\u003c/p\u003e","\u003cp\u003eReviewed and analyzed physician and referral arrangements on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003emultiple financial institutions\u003c/strong\u003e in connection with hospital public finance transactions to determine compliance with the Anti-Kickback Statute and Stark Law.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea multi-hospital system\u003c/strong\u003e in voluntarily disclosing pursuant to the OIG through the OIG Self-Disclosure Protocol its employment of individuals excluded from participation in federal healthcare programs.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":6,"guid":"6.capabilities","index":0,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":32,"guid":"32.capabilities","index":4,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":5,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":6,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":7,"source":"smartTags"},{"id":114,"guid":"114.capabilities","index":8,"source":"capabilities"}],"is_active":true,"last_name":"Robison","nick_name":"Adam","clerkships":[],"first_name":"Adam","title_rank":9999,"updated_by":101,"law_schools":[],"middle_name":" ","name_suffix":"","recognitions":[{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas (2019-2022)"},{"title":"\"Adam Robison has a very deep understanding of the specificities of healthcare transactions.\"","detail":"Chambers USA (2022)"},{"title":"Healthcare Super Lawyer: Texas","detail":"Super Lawyers, 2013–2016"},{"title":"Rising Star: Texas","detail":"Super Lawyers, 2010–2012"}],"linked_in_url":"https://www.linkedin.com/in/adam-robison-03538125/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eAdam Robison focuses on a wide range of matters involving healthcare providers and suppliers. A partner in our Healthcare practice, Adam represents healthcare clients in a variety of regulatory and transactional matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eAdam represents public and private hospital systems, academic medical centers, medical schools, children's hospitals, hospices, laboratories, physicians and suppliers in various regulatory and transactional matters.\u003c/p\u003e\n\u003cp\u003eAdam counsels clients concerning False Claims Act and Civil Monetary Penalty investigations, fraud and abuse, along with anti-kickback and physician self-referral issues, including physician contracting. He has also worked with clients on Medicare and Medicaid administrative overpayment appeals; Medicare and Medicaid self-disclosures; and compliance with the 60-day overpayment rule; as well as on Medicaid supplemental payment and 1115 Waiver programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Adam advises clients on a variety of transactional matters, including hospital joint operating company agreements, merger and acquisition agreements, and academic affiliation agreements.\u003c/p\u003e","matters":["\u003cp\u003eLitigation/Administrative Appeals\u003cbr /\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea large healthcare company\u003c/strong\u003e in obtaining an $18 million arbitration award against the sellers of a hospice pursuant to claims for indemnification and fraud related to a self-disclosure audit that Adam also facilitated.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea drug testing laboratory\u003c/strong\u003e in reducing a $31 million Medicare overpayment resulting in more than a $29 million overpayment reduction.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ean oncologist\u003c/strong\u003e before the Administrative Law Judge in a Medicare overpayment case resulting in the full reversal of the alleged multimillion-dollar overpayment.\u003c/p\u003e","\u003cp\u003eSuccessfully represented \u003cstrong data-redactor-tag=\"strong\"\u003ea coalition of children\u0026rsquo;s hospitals\u003c/strong\u003e in connection with dispute involving cost-settling certain Medicaid primary care case management payments resulting in multimillion-dollar settlements.\u003c/p\u003e","\u003cp\u003eNegotiated a $6 million settlement agreement for \u003cstrong data-redactor-tag=\"strong\"\u003ea children\u0026rsquo;s hospital\u003c/strong\u003e in connection with a dispute involving cost-settling certain Medicaid primary care case management payments.\u003c/p\u003e","\u003cp\u003eFalse Claims Act Matters and Settlements\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea county-owned hospital\u003c/strong\u003e in an approximate $21.75 million settlement of a federal False Claims Act \u003cem data-redactor-tag=\"em\"\u003equi tam\u003c/em\u003e lawsuit involving allegations of Stark Law and Anti-Kickback Statute violations without a Corporate Integrity Agreement.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea nursing home chain\u003c/strong\u003e in a $4 million settlement of federal and state False Claims Act lawsuit and negotiation of a Corporate Integrity Agreement related to ambulance arrangement allegations.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea hospital district\u003c/strong\u003e in a favorable $3.3 million settlement of federal and state False Claims Act lawsuit involving physician billing without a Corporate Integrity Agreement.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea national hospice\u003c/strong\u003e in negotiating an approximate $25 million settlement and negotiated Corporate Integrity Agreement based on allegations of lack of medically necessary services.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea county hospital district\u003c/strong\u003e in negotiating an approximate $15 million settlement and negotiated corporate compliance agreement related to allegations of lack of Medicare Secondary Payer issues and claims for prisoners.\u003c/p\u003e","\u003cp\u003eTransactions\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea medical school\u003c/strong\u003e in negotiating $100 plus million joint operating company and physician clinically integrated network agreements.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea medical school\u003c/strong\u003e in the annual negotiation of $220 plus million physician coverage and academic affiliation agreements.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state university/academic medical center\u003c/strong\u003e in the successful negotiation of a $338 million agreement with the state\u0026rsquo;s department of criminal justice for the provision of correctional healthcare services to state inmates.\u003c/p\u003e","\u003cp\u003eHealth Regulatory and Self-Disclosures\u003cbr /\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state medical school\u003c/strong\u003e in obtaining provider-based on-campus designation for its $66 million radiation oncology facility resulting in millions of dollars of additional reimbursement per year.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea state medical school\u003c/strong\u003e in obtaining a favorable advisory opinion from the Office of Inspector General related to the medical school\u0026rsquo;s prenatal care programs.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ean academic medical center hospital\u003c/strong\u003e in obtaining retroactive listing as a covered entity under the 340B drug discount program, resulting in $4.5 plus million in drug savings.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003emultiple hospital systems and providers\u003c/strong\u003e in self-disclosing overpayments to Medicare Administrative Contractors, the Office of Inspector General (self-disclosure protocol) and various state Medicaid agencies.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003evarious participants\u003c/strong\u003e regarding the development and implementation of Medicaid supplemental payment/1115 Waiver programs to provide enhanced Medicaid payments to hospitals and other providers located in multiple counties in Texas.\u003c/p\u003e","\u003cp\u003eReviewed and analyzed physician and referral arrangements on behalf of \u003cstrong data-redactor-tag=\"strong\"\u003emultiple financial institutions\u003c/strong\u003e in connection with hospital public finance transactions to determine compliance with the Anti-Kickback Statute and Stark Law.\u003c/p\u003e","\u003cp\u003eRepresented \u003cstrong data-redactor-tag=\"strong\"\u003ea multi-hospital system\u003c/strong\u003e in voluntarily disclosing pursuant to the OIG through the OIG Self-Disclosure Protocol its employment of individuals excluded from participation in federal healthcare programs.\u003c/p\u003e"],"recognitions":[{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas (2019-2022)"},{"title":"\"Adam Robison has a very deep understanding of the specificities of healthcare transactions.\"","detail":"Chambers USA (2022)"},{"title":"Healthcare Super Lawyer: Texas","detail":"Super Lawyers, 2013–2016"},{"title":"Rising Star: Texas","detail":"Super Lawyers, 2010–2012"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":89}]},"capability_group_id":2},"created_at":"2025-05-26T04:50:47.000Z","updated_at":"2025-05-26T04:50:47.000Z","searchable_text":"Robison{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Healthcare\", :detail=\u0026gt;\"Chambers USA, Texas (2019-2022)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Adam Robison has a very deep understanding of the specificities of healthcare transactions.\\\"\", :detail=\u0026gt;\"Chambers USA (2022)\"}{{ FIELD }}{:title=\u0026gt;\"Healthcare Super Lawyer: Texas\", :detail=\u0026gt;\"Super Lawyers, 2013–2016\"}{{ FIELD }}{:title=\u0026gt;\"Rising Star: Texas\", :detail=\u0026gt;\"Super Lawyers, 2010–2012\"}{{ FIELD }}Litigation/Administrative AppealsSuccessfully represented a large healthcare company in obtaining an $18 million arbitration award against the sellers of a hospice pursuant to claims for indemnification and fraud related to a self-disclosure audit that Adam also facilitated.{{ FIELD }}Successfully represented a drug testing laboratory in reducing a $31 million Medicare overpayment resulting in more than a $29 million overpayment reduction.{{ FIELD }}Represented an oncologist before the Administrative Law Judge in a Medicare overpayment case resulting in the full reversal of the alleged multimillion-dollar overpayment.{{ FIELD }}Successfully represented a coalition of children’s hospitals in connection with dispute involving cost-settling certain Medicaid primary care case management payments resulting in multimillion-dollar settlements.{{ FIELD }}Negotiated a $6 million settlement agreement for a children’s hospital in connection with a dispute involving cost-settling certain Medicaid primary care case management payments.{{ FIELD }}False Claims Act Matters and SettlementsRepresented a county-owned hospital in an approximate $21.75 million settlement of a federal False Claims Act qui tam lawsuit involving allegations of Stark Law and Anti-Kickback Statute violations without a Corporate Integrity Agreement.{{ FIELD }}Represented a nursing home chain in a $4 million settlement of federal and state False Claims Act lawsuit and negotiation of a Corporate Integrity Agreement related to ambulance arrangement allegations.{{ FIELD }}Represented a hospital district in a favorable $3.3 million settlement of federal and state False Claims Act lawsuit involving physician billing without a Corporate Integrity Agreement.{{ FIELD }}Represented a national hospice in negotiating an approximate $25 million settlement and negotiated Corporate Integrity Agreement based on allegations of lack of medically necessary services.{{ FIELD }}Represented a county hospital district in negotiating an approximate $15 million settlement and negotiated corporate compliance agreement related to allegations of lack of Medicare Secondary Payer issues and claims for prisoners.{{ FIELD }}TransactionsRepresented a medical school in negotiating $100 plus million joint operating company and physician clinically integrated network agreements.{{ FIELD }}Represented a medical school in the annual negotiation of $220 plus million physician coverage and academic affiliation agreements.{{ FIELD }}Represented a state university/academic medical center in the successful negotiation of a $338 million agreement with the state’s department of criminal justice for the provision of correctional healthcare services to state inmates.{{ FIELD }}Health Regulatory and Self-DisclosuresRepresented a state medical school in obtaining provider-based on-campus designation for its $66 million radiation oncology facility resulting in millions of dollars of additional reimbursement per year.{{ FIELD }}Represented a state medical school in obtaining a favorable advisory opinion from the Office of Inspector General related to the medical school’s prenatal care programs.{{ FIELD }}Represented an academic medical center hospital in obtaining retroactive listing as a covered entity under the 340B drug discount program, resulting in $4.5 plus million in drug savings.{{ FIELD }}Represented multiple hospital systems and providers in self-disclosing overpayments to Medicare Administrative Contractors, the Office of Inspector General (self-disclosure protocol) and various state Medicaid agencies.{{ FIELD }}Represented various participants regarding the development and implementation of Medicaid supplemental payment/1115 Waiver programs to provide enhanced Medicaid payments to hospitals and other providers located in multiple counties in Texas.{{ FIELD }}Reviewed and analyzed physician and referral arrangements on behalf of multiple financial institutions in connection with hospital public finance transactions to determine compliance with the Anti-Kickback Statute and Stark Law.{{ FIELD }}Represented a multi-hospital system in voluntarily disclosing pursuant to the OIG through the OIG Self-Disclosure Protocol its employment of individuals excluded from participation in federal healthcare programs.{{ FIELD }}Adam Robison focuses on a wide range of matters involving healthcare providers and suppliers. A partner in our Healthcare practice, Adam represents healthcare clients in a variety of regulatory and transactional matters.\nAdam represents public and private hospital systems, academic medical centers, medical schools, children's hospitals, hospices, laboratories, physicians and suppliers in various regulatory and transactional matters.\nAdam counsels clients concerning False Claims Act and Civil Monetary Penalty investigations, fraud and abuse, along with anti-kickback and physician self-referral issues, including physician contracting. He has also worked with clients on Medicare and Medicaid administrative overpayment appeals; Medicare and Medicaid self-disclosures; and compliance with the 60-day overpayment rule; as well as on Medicaid supplemental payment and 1115 Waiver programs.\nIn addition, Adam advises clients on a variety of transactional matters, including hospital joint operating company agreements, merger and acquisition agreements, and academic affiliation agreements. Partner Top Ranked Lawyer, Healthcare Chambers USA, Texas (2019-2022) \"Adam Robison has a very deep understanding of the specificities of healthcare transactions.\" Chambers USA (2022) Healthcare Super Lawyer: Texas Super Lawyers, 2013–2016 Rising Star: Texas Super Lawyers, 2010–2012 Brigham Young University J. Reuben Clark Law School South Texas College of Law South Texas College of Law Texas Litigation/Administrative AppealsSuccessfully represented a large healthcare company in obtaining an $18 million arbitration award against the sellers of a hospice pursuant to claims for indemnification and fraud related to a self-disclosure audit that Adam also facilitated. Successfully represented a drug testing laboratory in reducing a $31 million Medicare overpayment resulting in more than a $29 million overpayment reduction. Represented an oncologist before the Administrative Law Judge in a Medicare overpayment case resulting in the full reversal of the alleged multimillion-dollar overpayment. Successfully represented a coalition of children’s hospitals in connection with dispute involving cost-settling certain Medicaid primary care case management payments resulting in multimillion-dollar settlements. Negotiated a $6 million settlement agreement for a children’s hospital in connection with a dispute involving cost-settling certain Medicaid primary care case management payments. False Claims Act Matters and SettlementsRepresented a county-owned hospital in an approximate $21.75 million settlement of a federal False Claims Act qui tam lawsuit involving allegations of Stark Law and Anti-Kickback Statute violations without a Corporate Integrity Agreement. Represented a nursing home chain in a $4 million settlement of federal and state False Claims Act lawsuit and negotiation of a Corporate Integrity Agreement related to ambulance arrangement allegations. Represented a hospital district in a favorable $3.3 million settlement of federal and state False Claims Act lawsuit involving physician billing without a Corporate Integrity Agreement. Represented a national hospice in negotiating an approximate $25 million settlement and negotiated Corporate Integrity Agreement based on allegations of lack of medically necessary services. Represented a county hospital district in negotiating an approximate $15 million settlement and negotiated corporate compliance agreement related to allegations of lack of Medicare Secondary Payer issues and claims for prisoners. TransactionsRepresented a medical school in negotiating $100 plus million joint operating company and physician clinically integrated network agreements. Represented a medical school in the annual negotiation of $220 plus million physician coverage and academic affiliation agreements. Represented a state university/academic medical center in the successful negotiation of a $338 million agreement with the state’s department of criminal justice for the provision of correctional healthcare services to state inmates. Health Regulatory and Self-DisclosuresRepresented a state medical school in obtaining provider-based on-campus designation for its $66 million radiation oncology facility resulting in millions of dollars of additional reimbursement per year. Represented a state medical school in obtaining a favorable advisory opinion from the Office of Inspector General related to the medical school’s prenatal care programs. Represented an academic medical center hospital in obtaining retroactive listing as a covered entity under the 340B drug discount program, resulting in $4.5 plus million in drug savings. Represented multiple hospital systems and providers in self-disclosing overpayments to Medicare Administrative Contractors, the Office of Inspector General (self-disclosure protocol) and various state Medicaid agencies. Represented various participants regarding the development and implementation of Medicaid supplemental payment/1115 Waiver programs to provide enhanced Medicaid payments to hospitals and other providers located in multiple counties in Texas. Reviewed and analyzed physician and referral arrangements on behalf of multiple financial institutions in connection with hospital public finance transactions to determine compliance with the Anti-Kickback Statute and Stark Law. Represented a multi-hospital system in voluntarily disclosing pursuant to the OIG through the OIG Self-Disclosure Protocol its employment of individuals excluded from participation in federal healthcare programs.","searchable_name":"Adam Robison","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":101,"capability_group_featured":null,"home_page_featured":null},{"id":436367,"version":1,"owner_type":"Person","owner_id":2254,"payload":{"bio":"\u003cp\u003eKim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;actions, and in voluntary disclosures through agency programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\u003c/p\u003e\n\u003cp\u003eKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\u003c/p\u003e\n\u003cp\u003eKim holds a top ranking among Georgia healthcare lawyers in\u0026nbsp;\u003cem\u003eChambers USA,\u003c/em\u003e\u0026nbsp;and has been recognized for more than 10 years as one of\u0026nbsp;\u003cem\u003eThe\u003c/em\u003e\u0026nbsp;\u003cem\u003eBest Lawyers in America\u003c/em\u003e\u0026nbsp;for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by\u0026nbsp;\u003cem\u003eSuper Lawyers\u003c/em\u003e\u0026nbsp;since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;The Stark Law and Regulations,\u0026rdquo;\u0026nbsp;\u003cem\u003eCompliance Manual\u003c/em\u003e, Healthcare Compliance Association (2009, 2011 and 2016 updates)\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group,\u0026nbsp;\u003cem\u003eExecutive Summary\u003c/em\u003e\u0026nbsp;(December 2009), \u0026ldquo;The New Healthcare Delivery System:\u0026nbsp; What are Accountable Care Organizations and Medical Homes?\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), \u0026ldquo;Healthcare Reform Will Challenge Providers\u0026rsquo; Business Structures\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSpeaking Engagements\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, \u0026ldquo;The Regulatory Sprint to Coordinated Care:\u0026nbsp; Are We There Yet?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:\u0026nbsp; Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eABA Health Law Section Webinar, \u0026ldquo;Head Start:\u0026nbsp; What You Need to Know Now About the Newly Proposed AKS Regulations,\u0026rdquo; November 5, 2019.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017: \u0026nbsp;Participation in Panel Presentation, \u0026ldquo;Fulfilling Campaign Promises:\u0026nbsp; ACA Repeal and Replace\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAICPA Health Care Industry Conference, November 2016:\u0026nbsp; \u0026ldquo;ACA Update: Where are We and What\u0026rsquo;s Coming?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Program, December 2014:\u0026nbsp; \u0026ldquo;The New \u0026lsquo;Selfie\u0026rsquo;: Self Disclosures and Voluntary Repayments under Medicare\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:\u0026nbsp; Panel Presentation \u0026ndash; \u0026ldquo;Healthcare Reform Countdown\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eArkansas Hospital Association, August 2012:\u0026nbsp; \u0026ldquo;Update on Delivery System and Payment Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, August 2012:\u0026nbsp; \u0026ldquo;Recent Medicaid Developments from the Implementation of the Supreme Court\u0026rsquo;s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:\u0026nbsp; Panel Presentation, \u0026ldquo;Delivery System Evolution:\u0026nbsp; Competing on Cost and Quality\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eHCCA Southeast Regional Annual Conference, January 2012:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia State University College of Law and Center for Law, Health and Society, January 2012:\u0026nbsp; \u0026ldquo;Update -- The Progress of Healthcare Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, November 2011:\u0026nbsp; \u0026ldquo;Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:\u0026nbsp; Overview of the Final Rule and Agency Announcements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eTennessee Hospital Association Fall Compliance Conference, October 2011:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:\u0026nbsp; \u0026ldquo;Technology That Will Create Accountable Care:\u0026nbsp; Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Healthcare Financial Management Association, July 2011:\u0026nbsp; Accountable Care Organizations\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2011:\u0026nbsp; \u0026ldquo;Planning to Qualify as an Accountable Care Organization:\u0026nbsp; Proposed Rule and Agency Notices\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n\u003cli\u003eEast Tennessee Healthcare Fraud Working Group, April 2011:\u0026nbsp; \u0026ldquo;Health Care Reform and Compliance Issues\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:\u0026nbsp; \u0026ldquo;Legal and Regulatory Conflicts in PPACA\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, June 2010:\u0026nbsp; \u0026ldquo;Quality-Based Compensation in a New Era of Health Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Academy of Healthcare Attorneys, May 2010:\u0026nbsp; \u0026ldquo;Hospital-Physician Alignment\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, May 2010:\u0026nbsp; \u0026ldquo;Reform Driven Strategies and Tactics\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2010:\u0026nbsp; \u0026ldquo;Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e","slug":"kim-roeder","email":"kroeder@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":97}]},"expertise":[{"id":23,"guid":"23.capabilities","index":0,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":1,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":2,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":3,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":4,"source":"smartTags"}],"is_active":true,"last_name":"Roeder","nick_name":"Kim","clerkships":[],"first_name":"Kim","title_rank":9999,"updated_by":174,"law_schools":[],"middle_name":"H.","name_suffix":"","recognitions":[{"title":"Top ranking among Georgia healthcare lawyers ","detail":"Chambers USA"},{"title":"Healthcare Law ","detail":"The Best Lawyers in America, 10+ years"},{"title":"Georgia Super Lawyer ","detail":"Super Lawyers"},{"title":"Outstanding Healthcare Fraud and Compliance Lawyer ","detail":"Nightingale’s Healthcare News"}],"linked_in_url":null,"seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eKim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and\u0026nbsp;\u003cem\u003equi tam\u003c/em\u003e\u0026nbsp;actions, and in voluntary disclosures through agency programs.\u003c/p\u003e\n\u003cp\u003eIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\u003c/p\u003e\n\u003cp\u003eKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\u003c/p\u003e\n\u003cp\u003eKim holds a top ranking among Georgia healthcare lawyers in\u0026nbsp;\u003cem\u003eChambers USA,\u003c/em\u003e\u0026nbsp;and has been recognized for more than 10 years as one of\u0026nbsp;\u003cem\u003eThe\u003c/em\u003e\u0026nbsp;\u003cem\u003eBest Lawyers in America\u003c/em\u003e\u0026nbsp;for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by\u0026nbsp;\u003cem\u003eSuper Lawyers\u003c/em\u003e\u0026nbsp;since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in\u0026nbsp;\u003cem\u003eNightingale\u0026rsquo;s Healthcare News.\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026ldquo;The Stark Law and Regulations,\u0026rdquo;\u0026nbsp;\u003cem\u003eCompliance Manual\u003c/em\u003e, Healthcare Compliance Association (2009, 2011 and 2016 updates)\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group,\u0026nbsp;\u003cem\u003eExecutive Summary\u003c/em\u003e\u0026nbsp;(December 2009), \u0026ldquo;The New Healthcare Delivery System:\u0026nbsp; What are Accountable Care Organizations and Medical Homes?\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), \u0026ldquo;Healthcare Reform Will Challenge Providers\u0026rsquo; Business Structures\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSpeaking Engagements\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, \u0026ldquo;The Regulatory Sprint to Coordinated Care:\u0026nbsp; Are We There Yet?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:\u0026nbsp; Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eABA Health Law Section Webinar, \u0026ldquo;Head Start:\u0026nbsp; What You Need to Know Now About the Newly Proposed AKS Regulations,\u0026rdquo; November 5, 2019.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017: \u0026nbsp;Participation in Panel Presentation, \u0026ldquo;Fulfilling Campaign Promises:\u0026nbsp; ACA Repeal and Replace\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAICPA Health Care Industry Conference, November 2016:\u0026nbsp; \u0026ldquo;ACA Update: Where are We and What\u0026rsquo;s Coming?\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eKing \u0026amp; Spalding Roundtable Program, December 2014:\u0026nbsp; \u0026ldquo;The New \u0026lsquo;Selfie\u0026rsquo;: Self Disclosures and Voluntary Repayments under Medicare\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:\u0026nbsp; Panel Presentation \u0026ndash; \u0026ldquo;Healthcare Reform Countdown\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003eArkansas Hospital Association, August 2012:\u0026nbsp; \u0026ldquo;Update on Delivery System and Payment Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, August 2012:\u0026nbsp; \u0026ldquo;Recent Medicaid Developments from the Implementation of the Supreme Court\u0026rsquo;s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:\u0026nbsp; Panel Presentation, \u0026ldquo;Delivery System Evolution:\u0026nbsp; Competing on Cost and Quality\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eHCCA Southeast Regional Annual Conference, January 2012:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia State University College of Law and Center for Law, Health and Society, January 2012:\u0026nbsp; \u0026ldquo;Update -- The Progress of Healthcare Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, November 2011:\u0026nbsp; \u0026ldquo;Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:\u0026nbsp; Overview of the Final Rule and Agency Announcements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eTennessee Hospital Association Fall Compliance Conference, October 2011:\u0026nbsp; \u0026ldquo;Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:\u0026nbsp; \u0026ldquo;Technology That Will Create Accountable Care:\u0026nbsp; Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Healthcare Financial Management Association, July 2011:\u0026nbsp; Accountable Care Organizations\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2011:\u0026nbsp; \u0026ldquo;Planning to Qualify as an Accountable Care Organization:\u0026nbsp; Proposed Rule and Agency Notices\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cul\u003e\n\u003cli\u003eEast Tennessee Healthcare Fraud Working Group, April 2011:\u0026nbsp; \u0026ldquo;Health Care Reform and Compliance Issues\u0026rdquo;\u003c/li\u003e\n\u003cli\u003e20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:\u0026nbsp; \u0026ldquo;Legal and Regulatory Conflicts in PPACA\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, June 2010:\u0026nbsp; \u0026ldquo;Quality-Based Compensation in a New Era of Health Reform\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eGeorgia Academy of Healthcare Attorneys, May 2010:\u0026nbsp; \u0026ldquo;Hospital-Physician Alignment\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, May 2010:\u0026nbsp; \u0026ldquo;Reform Driven Strategies and Tactics\u0026rdquo;\u003c/li\u003e\n\u003cli\u003eAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\u003c/li\u003e\n\u003cli\u003eKing \u0026amp; Spalding Roundtable Program, April 2010:\u0026nbsp; \u0026ldquo;Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform\u0026rdquo;\u003c/li\u003e\n\u003c/ul\u003e","recognitions":[{"title":"Top ranking among Georgia healthcare lawyers ","detail":"Chambers USA"},{"title":"Healthcare Law ","detail":"The Best Lawyers in America, 10+ years"},{"title":"Georgia Super Lawyer ","detail":"Super Lawyers"},{"title":"Outstanding Healthcare Fraud and Compliance Lawyer ","detail":"Nightingale’s Healthcare News"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11804}]},"capability_group_id":2},"created_at":"2025-09-02T04:50:41.000Z","updated_at":"2025-09-02T04:50:41.000Z","searchable_text":"Roeder{{ FIELD }}{:title=\u0026gt;\"Top ranking among Georgia healthcare lawyers \", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"Healthcare Law \", :detail=\u0026gt;\"The Best Lawyers in America, 10+ years\"}{{ FIELD }}{:title=\u0026gt;\"Georgia Super Lawyer \", :detail=\u0026gt;\"Super Lawyers\"}{{ FIELD }}{:title=\u0026gt;\"Outstanding Healthcare Fraud and Compliance Lawyer \", :detail=\u0026gt;\"Nightingale’s Healthcare News\"}{{ FIELD }}Kim Roeder focuses on the healthcare sector, particularly with regard to compliance, investigations and transactions. As a partner in our Healthcare practice, Kim represents individual and institutional healthcare providers, along with suppliers, in a wide range of matters.\nKim advises healthcare suppliers and providers, including hospital systems, academic medical centers and physician practice groups, on implementing compliance programs as well as conducting compliance assessments and internal investigations. She frequently represents healthcare providers in responding to Department of Justice and Office of Inspector General investigations and qui tam actions, and in voluntary disclosures through agency programs.\nIn addition, Kim has extensive experience advising clients on Medicare and Medicaid reimbursement issues; federal and state self-referral and anti-kickback laws; delivery system reform; accountable care organizations; shared savings and incentive payment arrangements; clinically integrated networks; and hospital-physician employment relationships and other affiliations.\nKim is an Adjunct Professor at the Georgia State University College of Law. A frequent author and speaker before professional and trade groups, Kim is a member of the American Health Lawyers Association and the Health Care Compliance Association, and a former president of the Georgia Academy of Healthcare Attorneys.\nKim holds a top ranking among Georgia healthcare lawyers in Chambers USA, and has been recognized for more than 10 years as one of The Best Lawyers in America for Healthcare Law. In addition, she has been selected as a Georgia Super Lawyer by Super Lawyers since 2004, and named an Outstanding Healthcare Fraud and Compliance Lawyer in Nightingale’s Healthcare News.\nPublications\n\n“The Stark Law and Regulations,” Compliance Manual, Healthcare Compliance Association (2009, 2011 and 2016 updates)\nAmerican Health Lawyers Association, Business Law and Governance Practice Group, Executive Summary (December 2009), “The New Healthcare Delivery System:  What are Accountable Care Organizations and Medical Homes?”\nAmerican Health Lawyers Association, Business Law and Governance Practice Group, Business Law Update (September 9, 2009), “Healthcare Reform Will Challenge Providers’ Business Structures”\n\nSpeaking Engagements\n\n\nAmerican Health Lawyers Association, Physicians and Hospitals Law Institute, February 10-12, 2020, “The Regulatory Sprint to Coordinated Care:  Are We There Yet?”\n\n\nKing \u0026amp; Spalding Roundtable Webinars, November 7, 2019 and November 20, 2019: Recalculating:  Are the Major Stark, Anti-Kickback and CMP Proposed Rule Changes Taking Us in a New Direction?\n\n\nABA Health Law Section Webinar, “Head Start:  What You Need to Know Now About the Newly Proposed AKS Regulations,” November 5, 2019.\n\n\n26th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2017:  Participation in Panel Presentation, “Fulfilling Campaign Promises:  ACA Repeal and Replace”\n\n\nAICPA Health Care Industry Conference, November 2016:  “ACA Update: Where are We and What’s Coming?”\n\n\nKing \u0026amp; Spalding Roundtable Program, December 2014:  “The New ‘Selfie’: Self Disclosures and Voluntary Repayments under Medicare”\n\n\n22nd Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2013:  Panel Presentation – “Healthcare Reform Countdown”\n\nArkansas Hospital Association, August 2012:  “Update on Delivery System and Payment Reforms”\nKing \u0026amp; Spalding Roundtable Program, August 2012:  “Recent Medicaid Developments from the Implementation of the Supreme Court’s Ruling on PPACA, Enforcement Activities and Other Medicaid Reforms”\n21st Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2012:  Panel Presentation, “Delivery System Evolution:  Competing on Cost and Quality”\nHCCA Southeast Regional Annual Conference, January 2012:  “Compliance Issues in Accountable Care: Shared Savings, Bundled Payments and other Innovations”\nGeorgia State University College of Law and Center for Law, Health and Society, January 2012:  “Update -- The Progress of Healthcare Delivery System Reform”\nKing \u0026amp; Spalding Roundtable Program, November 2011:  “Qualifying as an Accountable Care Organization in the CMS Shared Savings Program:  Overview of the Final Rule and Agency Announcements”\nTennessee Hospital Association Fall Compliance Conference, October 2011:  “Compliance Issues in Accountable Care Organizations and Innovative Payment Arrangements”\nGeorgia Bio/Georgia Association of Healthcare Executives, October 2011:  “Technology That Will Create Accountable Care:  Legal Framework for Accountable Care Organizations and Innovative Payment Arrangements”\nGeorgia Healthcare Financial Management Association, July 2011:  Accountable Care Organizations\nKing \u0026amp; Spalding Roundtable Program, April 2011:  “Planning to Qualify as an Accountable Care Organization:  Proposed Rule and Agency Notices”\n\n\nEast Tennessee Healthcare Fraud Working Group, April 2011:  “Health Care Reform and Compliance Issues”\n20th Annual King \u0026amp; Spalding Health Law and Policy Forum, March 2011:  “Legal and Regulatory Conflicts in PPACA”\nAmerican Health Lawyers Association, June 2010:  “Quality-Based Compensation in a New Era of Health Reform”\nGeorgia Academy of Healthcare Attorneys, May 2010:  “Hospital-Physician Alignment”\nKing \u0026amp; Spalding Roundtable Program, May 2010:  “Reform Driven Strategies and Tactics”\nAmerican Health Lawyers Association, Moderator of national teleconference, April 2010, regarding Care Coordination Models\nKing \u0026amp; Spalding Roundtable Program, April 2010:  “Healthcare Reform Legislation -- Medicare, Medicaid and Delivery System Reform”\n Kim H Roeder Partner Top ranking among Georgia healthcare lawyers  Chambers USA Healthcare Law  The Best Lawyers in America, 10+ years Georgia Super Lawyer  Super Lawyers Outstanding Healthcare Fraud and Compliance Lawyer  Nightingale’s Healthcare News Cornell University Cornell Law School Case Western Reserve University Case Western Reserve University School of Law Georgia Health Care Compliance Association Georgia Academy of Healthcare Attorneys, Past President and Board Member American Bar Association, Health Law Section, Business and Corporate Section State Bar of Georgia, Health Law Section, Corporate Law Section Adjunct Professor, Georgia State University College of Law American Health Lawyers Association, Former Co-Chair of the Transactions Affinity Group of the Business Law and Governance Practice Group","searchable_name":"Kim H. Roeder","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":174,"capability_group_featured":null,"home_page_featured":null},{"id":445647,"version":1,"owner_type":"Person","owner_id":3646,"payload":{"bio":"\u003cp\u003eKristin Roshelli is a partner in King \u0026amp; Spalding\u0026rsquo;s Houston Healthcare practice. Kristin\u0026rsquo;s practice focuses on corporate and regulatory matters in the healthcare and life sciences industries.\u0026nbsp; She represents a broad range of prominent healthcare and life science\u0026nbsp;clients\u0026nbsp;on mergers and acquisitions, affiliations, general health law questions, and complex corporate governance and contracting matters. She has extensive experience structuring transactions, particularly as to complex arrangements involving health systems, physician practices, and academic medical centers.\u0026nbsp; Kristin has helped establish the legal and operational framework in connection with the startup of three new medical schools and multiple new health systems.\u0026nbsp; She is also a go-to lawyer for\u0026nbsp;leading pharmaceutical,\u0026nbsp;biotech, organ procurement and other large companies for assistance with complex collaboration arrangements with third parties and in establishing and negotiating\u0026nbsp;their supply chain and other key contracts.\u0026nbsp;\u0026nbsp;Her life sciences work often involves advising on product supply and manufacturing agreements, licensing arrangements, commercialization and distribution agreements, specialty pharmacy agreements,\u0026nbsp;research agreements and other complex collaboration arrangements and\u0026nbsp;key service and supply contracts.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eShe is Chambers-ranked for healthcare in Texas\u0026nbsp;and has been\u0026nbsp;recognized by \u003cem\u003eLegal 500\u003c/em\u003e as a \u0026ldquo;Recommended Key Lawyer,\u0026rdquo; by \u003cem\u003eTexas\u0026nbsp;Super Lawyers\u003c/em\u003e as a healthcare rising star,\u0026nbsp;and by\u0026nbsp;\u003cem\u003eTexas Lawyers\u003c/em\u003e with an \u0026ldquo;On the Rise Award,\u0026rdquo; which recognizes lawyers under the age of 40 who have wielded influence in their practice areas in Texas and beyond.\u0026nbsp; Prior to entering the legal field, Kristin served as a nurse in the United States Air Force, worked in the general counsel\u0026rsquo;s office of a large academic medical center, and practiced as a registered nurse in a medical intensive care unit.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e2016 Health Care Fraud and Abuse Top Ten List Reimbursement Advisor, Vol 32, No. 6, February 2017\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Plot Thickens for the Medicare Narrative Requirement,\u0026rdquo; Law360, February 2015\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When is a Hospital a \u0026lsquo;New Hospital?,\u0026rsquo;\u0026rdquo; Reimbursement Advisor, Vol. 30, No. 4, December 2014\u003c/li\u003e\n\u003c/ul\u003e","slug":"kristin-roshelli","email":"kroshelli@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":3777}]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":21,"guid":"21.capabilities","index":1,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":4,"source":"smartTags"},{"id":32,"guid":"32.capabilities","index":5,"source":"capabilities"}],"is_active":true,"last_name":"Roshelli","nick_name":"Kristin","clerkships":[{"name":"Law Clerk, P. Kevin Castel, U.S. District Court for the Southern District of New York","years_held":"2010-2011"}],"first_name":"Kristin","title_rank":9999,"updated_by":202,"law_schools":[{"id":2724,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2010-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"M.","name_suffix":"","recognitions":[{"title":"\"Kristin is very calm and intelligent, and extremely responsive. I always enjoy working with her.\"","detail":"Chambers USA"},{"title":"\"She is extremely knowledgeable, responsive and always able to navigate the most complex matters\"","detail":"Chambers USA"},{"title":"\"Kristin really understands our business well. She doesn't miss anything and is highly responsive.\"","detail":"Chambers USA"},{"title":"On the Rise Award","detail":"Texas Lawyer, 2020"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas (2021-2025)"},{"title":"\"She's very wise with her advice, as well as being detail-oriented and organized.\"","detail":"Chambers USA"}],"linked_in_url":null,"seodescription":"Kristin M. Roshelli is a lawyer of our Government Matters \u0026 Regulation Practice Group. Read more.","primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eKristin Roshelli is a partner in King \u0026amp; Spalding\u0026rsquo;s Houston Healthcare practice. Kristin\u0026rsquo;s practice focuses on corporate and regulatory matters in the healthcare and life sciences industries.\u0026nbsp; She represents a broad range of prominent healthcare and life science\u0026nbsp;clients\u0026nbsp;on mergers and acquisitions, affiliations, general health law questions, and complex corporate governance and contracting matters. She has extensive experience structuring transactions, particularly as to complex arrangements involving health systems, physician practices, and academic medical centers.\u0026nbsp; Kristin has helped establish the legal and operational framework in connection with the startup of three new medical schools and multiple new health systems.\u0026nbsp; She is also a go-to lawyer for\u0026nbsp;leading pharmaceutical,\u0026nbsp;biotech, organ procurement and other large companies for assistance with complex collaboration arrangements with third parties and in establishing and negotiating\u0026nbsp;their supply chain and other key contracts.\u0026nbsp;\u0026nbsp;Her life sciences work often involves advising on product supply and manufacturing agreements, licensing arrangements, commercialization and distribution agreements, specialty pharmacy agreements,\u0026nbsp;research agreements and other complex collaboration arrangements and\u0026nbsp;key service and supply contracts.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eShe is Chambers-ranked for healthcare in Texas\u0026nbsp;and has been\u0026nbsp;recognized by \u003cem\u003eLegal 500\u003c/em\u003e as a \u0026ldquo;Recommended Key Lawyer,\u0026rdquo; by \u003cem\u003eTexas\u0026nbsp;Super Lawyers\u003c/em\u003e as a healthcare rising star,\u0026nbsp;and by\u0026nbsp;\u003cem\u003eTexas Lawyers\u003c/em\u003e with an \u0026ldquo;On the Rise Award,\u0026rdquo; which recognizes lawyers under the age of 40 who have wielded influence in their practice areas in Texas and beyond.\u0026nbsp; Prior to entering the legal field, Kristin served as a nurse in the United States Air Force, worked in the general counsel\u0026rsquo;s office of a large academic medical center, and practiced as a registered nurse in a medical intensive care unit.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e2016 Health Care Fraud and Abuse Top Ten List Reimbursement Advisor, Vol 32, No. 6, February 2017\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Plot Thickens for the Medicare Narrative Requirement,\u0026rdquo; Law360, February 2015\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When is a Hospital a \u0026lsquo;New Hospital?,\u0026rsquo;\u0026rdquo; Reimbursement Advisor, Vol. 30, No. 4, December 2014\u003c/li\u003e\n\u003c/ul\u003e","recognitions":[{"title":"\"Kristin is very calm and intelligent, and extremely responsive. I always enjoy working with her.\"","detail":"Chambers USA"},{"title":"\"She is extremely knowledgeable, responsive and always able to navigate the most complex matters\"","detail":"Chambers USA"},{"title":"\"Kristin really understands our business well. She doesn't miss anything and is highly responsive.\"","detail":"Chambers USA"},{"title":"On the Rise Award","detail":"Texas Lawyer, 2020"},{"title":"Top Ranked Lawyer, Healthcare","detail":"Chambers USA, Texas (2021-2025)"},{"title":"\"She's very wise with her advice, as well as being detail-oriented and organized.\"","detail":"Chambers USA"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11456}]},"capability_group_id":2},"created_at":"2026-02-06T21:25:46.000Z","updated_at":"2026-02-06T21:25:46.000Z","searchable_text":"Roshelli{{ FIELD }}{:title=\u0026gt;\"\\\"Kristin is very calm and intelligent, and extremely responsive. I always enjoy working with her.\\\"\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"\\\"She is extremely knowledgeable, responsive and always able to navigate the most complex matters\\\"\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"\\\"Kristin really understands our business well. She doesn't miss anything and is highly responsive.\\\"\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}{:title=\u0026gt;\"On the Rise Award\", :detail=\u0026gt;\"Texas Lawyer, 2020\"}{{ FIELD }}{:title=\u0026gt;\"Top Ranked Lawyer, Healthcare\", :detail=\u0026gt;\"Chambers USA, Texas (2021-2025)\"}{{ FIELD }}{:title=\u0026gt;\"\\\"She's very wise with her advice, as well as being detail-oriented and organized.\\\"\", :detail=\u0026gt;\"Chambers USA\"}{{ FIELD }}Kristin Roshelli is a partner in King \u0026amp; Spalding’s Houston Healthcare practice. Kristin’s practice focuses on corporate and regulatory matters in the healthcare and life sciences industries.  She represents a broad range of prominent healthcare and life science clients on mergers and acquisitions, affiliations, general health law questions, and complex corporate governance and contracting matters. She has extensive experience structuring transactions, particularly as to complex arrangements involving health systems, physician practices, and academic medical centers.  Kristin has helped establish the legal and operational framework in connection with the startup of three new medical schools and multiple new health systems.  She is also a go-to lawyer for leading pharmaceutical, biotech, organ procurement and other large companies for assistance with complex collaboration arrangements with third parties and in establishing and negotiating their supply chain and other key contracts.  Her life sciences work often involves advising on product supply and manufacturing agreements, licensing arrangements, commercialization and distribution agreements, specialty pharmacy agreements, research agreements and other complex collaboration arrangements and key service and supply contracts. \nShe is Chambers-ranked for healthcare in Texas and has been recognized by Legal 500 as a “Recommended Key Lawyer,” by Texas Super Lawyers as a healthcare rising star, and by Texas Lawyers with an “On the Rise Award,” which recognizes lawyers under the age of 40 who have wielded influence in their practice areas in Texas and beyond.  Prior to entering the legal field, Kristin served as a nurse in the United States Air Force, worked in the general counsel’s office of a large academic medical center, and practiced as a registered nurse in a medical intensive care unit. \nPublications\n\n2016 Health Care Fraud and Abuse Top Ten List Reimbursement Advisor, Vol 32, No. 6, February 2017\n“The Plot Thickens for the Medicare Narrative Requirement,” Law360, February 2015\n“When is a Hospital a ‘New Hospital?,’” Reimbursement Advisor, Vol. 30, No. 4, December 2014\n Kristin Roshelli lawyer Partner \"Kristin is very calm and intelligent, and extremely responsive. I always enjoy working with her.\" Chambers USA \"She is extremely knowledgeable, responsive and always able to navigate the most complex matters\" Chambers USA \"Kristin really understands our business well. She doesn't miss anything and is highly responsive.\" Chambers USA On the Rise Award Texas Lawyer, 2020 Top Ranked Lawyer, Healthcare Chambers USA, Texas (2021-2025) \"She's very wise with her advice, as well as being detail-oriented and organized.\" Chambers USA University of Pennsylvania University of Pennsylvania Law School St. John's University St. John's University School of Law U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York New Jersey New York Texas American Bar Association (2014) American Health Lawyers Association (2011) New York State Bar Association (2011) Houston Young Lawyers Association (2014) Law Clerk, P. Kevin Castel, U.S. District Court for the Southern District of New York","searchable_name":"Kristin M. Roshelli","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":435809,"version":1,"owner_type":"Person","owner_id":6591,"payload":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","slug":"sean-royall","email":"sroyall@kslaw.com","phone":null,"matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":129,"guid":"129.capabilities","index":0,"source":"capabilities"},{"id":5,"guid":"5.capabilities","index":1,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":2,"source":"capabilities"},{"id":6,"guid":"6.capabilities","index":3,"source":"capabilities"},{"id":118,"guid":"118.capabilities","index":4,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":5,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":6,"source":"capabilities"},{"id":102,"guid":"102.capabilities","index":7,"source":"capabilities"},{"id":1147,"guid":"1147.smart_tags","index":8,"source":"smartTags"},{"id":750,"guid":"750.smart_tags","index":9,"source":"smartTags"},{"id":1141,"guid":"1141.smart_tags","index":10,"source":"smartTags"},{"id":3,"guid":"3.capabilities","index":11,"source":"capabilities"},{"id":23,"guid":"23.capabilities","index":12,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":13,"source":"capabilities"},{"id":2,"guid":"2.capabilities","index":14,"source":"capabilities"},{"id":106,"guid":"106.capabilities","index":15,"source":"capabilities"},{"id":761,"guid":"761.smart_tags","index":16,"source":"smartTags"},{"id":765,"guid":"765.smart_tags","index":17,"source":"smartTags"},{"id":952,"guid":"952.smart_tags","index":18,"source":"smartTags"},{"id":1,"guid":"1.capabilities","index":19,"source":"capabilities"},{"id":1248,"guid":"1248.smart_tags","index":20,"source":"smartTags"}],"is_active":true,"last_name":"Royall","nick_name":"M. Sean","clerkships":[{"name":"Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit","years_held":"1990 - 1991"}],"first_name":"M. Sean","title_rank":9999,"updated_by":202,"law_schools":[{"id":2174,"meta":{"degree":"J.D.","honors":"cum laude, Law Review","is_law_school":"1","graduation_date":"1990-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"","name_suffix":"","recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}],"linked_in_url":"https://www.linkedin.com/in/sean-royall-16964b232/","seodescription":null,"primary_title_id":15,"translated_fields":{"en":{"bio":"\u003cp\u003eSean Royall serves as the firm\u0026rsquo;s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country\u0026rsquo;s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC\u0026rsquo;s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition\u0026nbsp;to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\u003c/p\u003e\n\u003cp\u003eWhile\u0026nbsp;in government, Sean\u0026nbsp;was the lead trial lawyer in the FTC\u0026rsquo;s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company\u0026rsquo;s victory over the Department of Justice\u0026rsquo;s antitrust challenge to AT\u0026amp;T\u0026rsquo;s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\u003c/p\u003e\n\u003cp\u003eSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC\u0026rsquo;s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFor well more than a decade, Sean has been given a Band 1 ranking by\u0026nbsp;\u003cem\u003eChambers USA\u0026nbsp;\u003c/em\u003e(2007-2025)\u003cem\u003e,\u0026nbsp;\u003c/em\u003ewhich has described him as \u0026ldquo;top of the field,\u0026rdquo; \u0026ldquo;a star in the antitrust world both in counseling and litigation,\u0026rdquo; and an \u0026ldquo;extremely talented lawyer and exceptional litigator.\u0026rdquo;\u003c/p\u003e\n\u003cp\u003eSean\u0026rsquo;s other recognitions include being ranked in\u0026nbsp;\u003cem\u003eChambers Global\u003c/em\u003e\u0026nbsp;for Antitrust \u0026ndash; USA (2020-2023); endorsed as \u0026ldquo;Highly Recommended (Texas)\u0026rdquo; by\u0026nbsp;\u003cem\u003eGlobal Competition Review\u003c/em\u003e\u0026nbsp;(2025); named a \u0026ldquo;Litigation Star\u0026rdquo; for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by\u0026nbsp;\u003cem\u003eBenchmark Litigation\u003c/em\u003e\u0026nbsp;(2023). He is named by \u003cem\u003eLexology\u003c/em\u003e as a \"Competition Thought Leader\" (2025);\u0026nbsp;\u003cem\u003e\u0026nbsp;The Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Antitrust Lawyer of the Year\u0026rdquo; (2015, 2018); and \u003cem\u003eThe Best Lawyers in America\u003c/em\u003e\u0026nbsp;as \u0026ldquo;Litigation: Antitrust Lawyer of the Year\u0026rdquo; (2019). He has also been named to the \u0026ldquo;All-Star List\u0026rdquo; by BTI Services (2017) and deemed a \u0026ldquo;National Antitrust MVP\u0026rdquo; by\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e\u0026nbsp;(2015); a \u0026ldquo;Mergers and Acquisitions and Antitrust Trailblazer\u0026rdquo; by\u0026nbsp;\u003cem\u003eNational Law Journal\u003c/em\u003e\u0026nbsp;(2015); and a \u0026ldquo;Life Sciences Star\u0026rdquo; in Antitrust (2022) and Competition and Antitrust (2018\u0026ndash;2019) by\u0026nbsp;\u003cem\u003eLMG Life Sciences\u003c/em\u003e. For the fourth year in a row, Sean was also named by \u003cem\u003eLawdragon \u003c/em\u003eas one of the \"500 Leading Litigators in America.\"\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublications\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, and as an editor of the ABA\u0026rsquo;s\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e\u0026nbsp;magazine and of the Von Kalinowski treatise on\u0026nbsp;\u003cem\u003eAntitrust Laws and Trade Regulation\u003c/em\u003e.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuthor, \u0026ldquo;A Google Breakup Would Serve Progressive Aims and Punish Business,\u0026rdquo; \u003cem\u003eBloomberg Law\u003c/em\u003e, October 5, 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s Punctuated Equilibrium,\u0026rdquo; \u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 2023.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;The FTC\u0026rsquo;s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, September 9, 2022.\u003c/li\u003e\n\u003cli\u003eAuthor, \u0026ldquo;Antitrust and Consumer Protection at Last Converge,\u0026rdquo;\u0026nbsp;\u003cem\u003eCorporate Counsel\u003c/em\u003e, April 27, 2022.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;CFPB May Fill Enforcement Gap After FTC\u0026rsquo;s High Court Loss,\u0026rdquo;\u0026nbsp;\u003cem\u003eLaw360\u003c/em\u003e, May 6, 2021.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;By the Numbers: 5 Practices That Could Drive Big Law in 2021,\u0026rdquo;\u0026nbsp;\u003cem\u003eBloomberg Law\u003c/em\u003e, December 23, 2020.\u003c/li\u003e\n\u003cli\u003eQuoted in, \u0026ldquo;\u0026lsquo;Hipster Antitrust\u0026rsquo; Comes for Joe Biden,\u0026rdquo;\u0026nbsp;\u003cem\u003eNew York Times\u003c/em\u003e, November 13, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,\u0026rdquo;\u003cem\u003e\u0026nbsp;ABA Antitrust Magazine\u003c/em\u003e, August 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Intersection of Antitrust and the False Claims Act,\u0026rdquo;\u0026nbsp;\u003cem\u003eHeadnotes\u003c/em\u003e, Dallas Bar Association, June 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, March 9, 2020.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, December 12, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, September 3, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, August 7, 2019.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Ninth Circuit Judges Call for En Banc Review of FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, January 15, 2019.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Lessons from FTC\u0026rsquo;s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, October 23, 2018.\u003c/li\u003e\n\u003cli\u003eCo-author, \u0026ldquo;Are Disgorgement\u0026rsquo;s Days Numbered?\u0026nbsp;\u003cem\u003eKokesh v. SEC\u003c/em\u003e\u0026nbsp;May Foreshadow Curtailment of the FTC\u0026rsquo;s Authority to Obtain Monetary Relief,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2018.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Will\u0026nbsp;\u003cem\u003eKokesh v. FTC\u003c/em\u003e\u0026nbsp;Put a Kink in the Federal Trade Commission\u0026rsquo;s Disgorgement Hose?\u0026rdquo;\u0026nbsp;\u003cem\u003eWLF Legal Pulse\u003c/em\u003e, July 10, 2017.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Antitrust Scrutiny of Pharmaceutical Product Hopping,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2013.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;When Mergers Become a Private Matter: An Updated Antitrust Primer,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2012.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Fall 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Spring 2010.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Change?: Merger Enforcement in the New Administration,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe Advocate\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Deterring \u0026lsquo;Patent Ambush\u0026rsquo; in Standard Setting: Lessons from Rambus and Qualcomm,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2009.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The FTC\u0026rsquo;s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,\u0026rdquo;\u0026nbsp;\u003cem\u003eABA Antitrust Magazine\u003c/em\u003e, Summer 2008.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Avoiding the Scarlet \u0026lsquo;S\u0026rsquo;: The Modern Challenges of Document Preservation and Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, June 2005.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;The Art of Destruction,\u0026rdquo;\u0026nbsp;\u003cem\u003eThe American Lawyer\u003c/em\u003e, September 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2004.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Administrative Litigation at the FTC: Past, Present, and Future,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2003.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust\u003c/em\u003e, 2001.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Coping with the Antitrust Risks of Technological Integration,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 2000.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Disaggregation\u0026nbsp;of Antitrust Damages,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1997.\u003c/li\u003e\n\u003cli\u003e\u0026ldquo;Post-Chicago Economics,\u0026rdquo;\u0026nbsp;\u003cem\u003eAntitrust Law Journal\u003c/em\u003e, 1995.\u003c/li\u003e\n\u003c/ul\u003e","matters":["\u003cp\u003e\u003cstrong\u003eLitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIn re Namenda Indirect Purchaser Antitrust Litigation\u003c/em\u003e\u0026nbsp;(S.D.N.Y.) \u0026ndash; Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of \u0026ldquo;product hopping\u0026rdquo; and a challenged \u0026ldquo;reverse payment\u0026rdquo; patent settlement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Restasis Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D.N.Y.) \u0026ndash; Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Silbersher v. Allergan\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re JUUL Labs., Inc. Antitrust Litigation\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u0026nbsp;\u003c/em\u003e(C.D. Cal.) \u0026ndash; Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T\u0026rsquo;s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors\u0026rsquo; negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T\u0026rsquo;s motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Lending Club\u003c/em\u003e\u0026nbsp;(N.D. Cal.) \u0026ndash; Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club\u0026rsquo;s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AT\u0026amp;T\u003c/em\u003e\u0026nbsp;(D.D.C. \u0026amp; D.C. Cir.) \u0026ndash; Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company\u0026rsquo;s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eSureShot v. Topgolf\u0026nbsp;\u003c/em\u003e(S.D. Tex. \u0026amp; 5th Cir.) \u0026ndash; Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eCipla v. Amgen\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eShire v. Allergan\u003c/em\u003e\u0026nbsp;(D. N.J.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eHartig v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del. \u0026amp; 3d Cir.) \u0026ndash; Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged \u0026ldquo;product hopping\u0026rdquo;; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eApotex v. Allergan\u003c/em\u003e\u0026nbsp;(D. Del.) \u0026ndash; Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful \u0026ldquo;product hopping\u0026rdquo;; obtained highly favorable settlement after the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAmphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. ex rel. Amphastar v. Sanofi-Aventis\u003c/em\u003e\u0026nbsp;(C.D. Cal \u0026amp; 9th Cir.) \u0026ndash; Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eFTC v. Commerce Planet\u003c/em\u003e\u0026nbsp;(9th Cir.) \u0026ndash; Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eStanwood v. Mary Kay Cosmetics\u003c/em\u003e\u0026nbsp;(C.D. Cal.) \u0026ndash; Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company\u0026rsquo;s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAvery Dennison v. 3M Corp.\u003c/em\u003e\u0026nbsp;(D. Minn.) \u0026ndash; Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eIn re Wellbutrin XL Antitrust Litigation\u003c/em\u003e\u0026nbsp;(E.D. Pa.) \u0026ndash; Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eTodd v. Exxon, et al.\u0026nbsp;\u003c/em\u003e(S.D.N.Y.) \u0026ndash; Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eNeon Systems v. BMC Software\u003c/em\u003e\u0026nbsp;(Tex. Civ.) \u0026ndash; Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eAtlantic Coast Airlines v. Mesa Airlines\u003c/em\u003e\u0026nbsp;(D.D.C.) \u0026ndash; Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Forge v. Sempra Energy\u003c/em\u003e\u0026nbsp;(Sup. Ct. Cal.) \u0026ndash; Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLonghorn Partners Pipeline Co. v. Holly Corp.\u003c/em\u003e\u0026nbsp;(W.D. Tex.) \u0026ndash; Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eU.S. v. AMR Corp.\u003c/em\u003e\u0026nbsp;(D. Kansas) \u0026ndash; Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*\u003c/p\u003e","\u003cp\u003e\u003cem\u003eLitton Systems v. Honeywell\u003c/em\u003e\u0026nbsp;(C.D. Cal. \u0026amp; 9th Cir.) \u0026ndash; Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.\u003c/p\u003e","\u003cp\u003e\u003cem\u003eContinental Airlines v. American Airlines\u003c/em\u003e\u0026nbsp;(S.D. Tex.) \u0026ndash;Represented American Airlines in this suit alleging improper predatory pricing relating to American\u0026rsquo;s introduction of a new fare structure; obtained favorable jury verdict.\u003c/p\u003e","\u003cp\u003e\u003cstrong\u003eGovernment Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKurbo/WW Inc. \u0026ndash; Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.\u003c/p\u003e","\u003cp\u003eGoogle/Fitbit \u0026ndash; Counsel for Fitbit in connection with DOJ investigation of Google\u0026rsquo;s successful US$2.1 billion acquisition of Fitbit.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/Time Warner \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$85 billion acquisition of Time Warner.\u003c/p\u003e","\u003cp\u003eAT\u0026amp;T/DirecTV \u0026ndash; Counsel for AT\u0026amp;T in connection with DOJ investigation of the company\u0026rsquo;s successful US$48 billion acquisition of DirecTV.\u003c/p\u003e","\u003cp\u003eFacebook \u0026ndash; Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.\u003c/p\u003e","\u003cp\u003eBazaarvoice \u0026ndash; Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.\u003c/p\u003e","\u003cp\u003eTicketmaster/LiveNation \u0026ndash; Lead counsel for Ticketmaster in connection with DOJ investigation of the company\u0026rsquo;s US$2.5 billion acquisition of LiveNation.\u003c/p\u003e","\u003cp\u003eWilliams Cos. \u0026ndash; Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.\u003c/p\u003e","\u003cp\u003eLeon Max/Max Studios \u0026ndash; Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.\u003c/p\u003e","\u003cp\u003eValueClick \u0026ndash; Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.\u003c/p\u003e","\u003cp\u003eAllergan \u0026ndash; Lead counsel for Allergan in connection with FTC investigation of the company\u0026rsquo;s successful US$3.2 billion acquisition of Inamed Corp.\u003c/p\u003e","\u003cp\u003eWatson Wyatt \u0026ndash; Lead counsel for Watson Wyatt in connection with DOJ investigation of the company\u0026rsquo;s successful US$3.5 billion acquisition of Towers Perrin.\u003c/p\u003e","\u003cp\u003eUnited Defense \u0026ndash; Lead counsel for United Defense in DOJ investigation of BAe\u0026rsquo;s successful US$4.2 billion acquisition of UDI.\u003c/p\u003e","\u003cp\u003eAncestry.com \u0026ndash; Lead counsel for Ancestry.com in connection with FTC investigation of the company\u0026rsquo;s successful acquisition of Archive.com.\u003c/p\u003e","\u003cp\u003eEndocare \u0026ndash; Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.\u003c/p\u003e","\u003cp\u003eDiedrichCoffee \u0026ndash; Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.\u003c/p\u003e","\u003cp\u003eNumerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.\u003c/p\u003e"],"recognitions":[{"title":"Ranked Band 1 for Antitrust, Texas","detail":"Chambers USA, 2007–2023"},{"title":"Top ranked for Antitrust USA","detail":"Chambers Global, 2020–2023"},{"title":"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work","detail":"Benchmark Litigation, 2023"},{"title":"Named “Highly Recommended (Texas)”","detail":"Global Competition Review, 2022"},{"title":"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)","detail":"LMG Life Sciences"},{"title":"Named as one of “500 Leading Litigators in America”","detail":"Lawdragon, 2022 and 2024"},{"title":"Listed","detail":"Who’s Who Legal in Competition, 2021"},{"title":"Named “Litigation: Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2019"},{"title":"Named “Antitrust Lawyer of the Year”","detail":"The Best Lawyers in America, 2015 and 2018"},{"title":"Listed in “All-Star List”","detail":"BTI Services, 2017"},{"title":"Named “Mergers and Acquisitions and Antitrust Trailblazer”","detail":"National Law Journal, 2015"},{"title":"Named “National Antitrust MVP”","detail":"Law360, 2015"}]},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11010}]},"capability_group_id":3},"created_at":"2025-08-27T18:44:30.000Z","updated_at":"2025-08-27T18:44:30.000Z","searchable_text":"Royall{{ FIELD }}{:title=\u0026gt;\"Ranked Band 1 for Antitrust, Texas\", :detail=\u0026gt;\"Chambers USA, 2007–2023\"}{{ FIELD }}{:title=\u0026gt;\"Top ranked for Antitrust USA\", :detail=\u0026gt;\"Chambers Global, 2020–2023\"}{{ FIELD }}{:title=\u0026gt;\"Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work\", :detail=\u0026gt;\"Benchmark Litigation, 2023\"}{{ FIELD }}{:title=\u0026gt;\"Named “Highly Recommended (Texas)”\", :detail=\u0026gt;\"Global Competition Review, 2022\"}{{ FIELD }}{:title=\u0026gt;\"Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019)\", :detail=\u0026gt;\"LMG Life Sciences\"}{{ FIELD }}{:title=\u0026gt;\"Named as one of “500 Leading Litigators in America”\", :detail=\u0026gt;\"Lawdragon, 2022 and 2024\"}{{ FIELD }}{:title=\u0026gt;\"Listed\", :detail=\u0026gt;\"Who’s Who Legal in Competition, 2021\"}{{ FIELD }}{:title=\u0026gt;\"Named “Litigation: Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2019\"}{{ FIELD }}{:title=\u0026gt;\"Named “Antitrust Lawyer of the Year”\", :detail=\u0026gt;\"The Best Lawyers in America, 2015 and 2018\"}{{ FIELD }}{:title=\u0026gt;\"Listed in “All-Star List”\", :detail=\u0026gt;\"BTI Services, 2017\"}{{ FIELD }}{:title=\u0026gt;\"Named “Mergers and Acquisitions and Antitrust Trailblazer”\", :detail=\u0026gt;\"National Law Journal, 2015\"}{{ FIELD }}{:title=\u0026gt;\"Named “National Antitrust MVP”\", :detail=\u0026gt;\"Law360, 2015\"}{{ FIELD }}Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement.{{ FIELD }}In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments.{{ FIELD }}U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry.{{ FIELD }}In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement.{{ FIELD }}U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss.{{ FIELD }}FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably.{{ FIELD }}U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit.{{ FIELD }}SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance.{{ FIELD }}Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal.{{ FIELD }}Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss.{{ FIELD }}Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court.{{ FIELD }}Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery.{{ FIELD }}Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims.{{ FIELD }}U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit.{{ FIELD }}FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability.{{ FIELD }}Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims.{{ FIELD }}Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery.{{ FIELD }}In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims.{{ FIELD }}Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information.{{ FIELD }}Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial.{{ FIELD }}Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement.{{ FIELD }}Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims.{{ FIELD }}Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines.{{ FIELD }}U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.*{{ FIELD }}Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue.{{ FIELD }}Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict.{{ FIELD }}Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement.{{ FIELD }}Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit.{{ FIELD }}AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner.{{ FIELD }}AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV.{{ FIELD }}Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation.{{ FIELD }}Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations.{{ FIELD }}Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation.{{ FIELD }}Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP.{{ FIELD }}Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments.{{ FIELD }}ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues.{{ FIELD }}Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp.{{ FIELD }}Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin.{{ FIELD }}United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI.{{ FIELD }}Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com.{{ FIELD }}Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical.{{ FIELD }}DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters.{{ FIELD }}Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.{{ FIELD }}Sean Royall serves as the firm’s Global Practice Head for Antitrust and Consumer Protection. He has spent his entire career handling complex litigation matters and government investigations and is among the country’s most experienced and highly regarded antitrust lawyers. He focuses broadly on antitrust and consumer protection litigation, government investigations, and counseling, and is a highly experienced courtroom litigator with a stellar track record for winning high-stakes cases. Sean is equally effective navigating complex government investigations and advising clients on the details of a wide range of strategic antitrust and consumer protection issues.\nSean previously served at the Federal Trade Commission (FTC) as the Deputy Director of the FTC’s Bureau of Competition. His antitrust career, both in government and private practice, has included work on many major mergers and acquisitions, as well as lead roles in complex litigation matters that often intersect with other areas of law, including patent law, various federal regulatory regimes, consumer protection, and privacy. Sean has deep experience representing clients across a range of industries, including biopharma, healthcare, e-commerce, telecom, financial services, energy, transportation, software, and semiconductors. In addition to his work on U.S. antitrust and consumer protection matters, Sean has worked and advised on many similar cases and investigations in Europe and other parts of the world.\nWhile in government, Sean was the lead trial lawyer in the FTC’s landmark monopolization suit against computer chip maker Rambus Inc., a novel case that established new legal standards applicable to patent disclosure within industry standard-setting consortiums. More recently, Sean played an important role on the trial team for AT\u0026amp;T in the company’s victory over the Department of Justice’s antitrust challenge to AT\u0026amp;T’s US$85 billion acquisition of Time Warner. In addition to his trial experience, Sean has successfully argued appeals in courts around the country.\nSean also has a nationally prominent reputation for his work in the consumer protection area, where he has particularly deep experience handling FTC investigations and associated litigation focused on advertising, marketing, privacy, and data security issues. In 2018-19, for example, Sean served as lead counsel for Facebook in connection with the FTC’s extensive privacy-related investigation and subsequent settlement. He brings to this area of his practice deep knowledge of applicable law and agency practice, as well as the skills of an accomplished litigator. \nFor well more than a decade, Sean has been given a Band 1 ranking by Chambers USA (2007-2025), which has described him as “top of the field,” “a star in the antitrust world both in counseling and litigation,” and an “extremely talented lawyer and exceptional litigator.”\nSean’s other recognitions include being ranked in Chambers Global for Antitrust – USA (2020-2023); endorsed as “Highly Recommended (Texas)” by Global Competition Review (2025); named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work by Benchmark Litigation (2023). He is named by Lexology as a \"Competition Thought Leader\" (2025);  The Best Lawyers in America as “Antitrust Lawyer of the Year” (2015, 2018); and The Best Lawyers in America as “Litigation: Antitrust Lawyer of the Year” (2019). He has also been named to the “All-Star List” by BTI Services (2017) and deemed a “National Antitrust MVP” by Law360 (2015); a “Mergers and Acquisitions and Antitrust Trailblazer” by National Law Journal (2015); and a “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) by LMG Life Sciences. For the fourth year in a row, Sean was also named by Lawdragon as one of the \"500 Leading Litigators in America.\"\nPublications\nSean has written extensively on a wide range of topics relevant to, among other things, antitrust law and policy, consumer protection, privacy, FTC process and remedies, class action antitrust litigation, pharmaceutical antitrust, and standard setting. Sean previously served as Editorial Chair of the ABA’s Antitrust Law Journal, and as an editor of the ABA’s Antitrust magazine and of the Von Kalinowski treatise on Antitrust Laws and Trade Regulation.\n\nAuthor, “A Google Breakup Would Serve Progressive Aims and Punish Business,” Bloomberg Law, October 5, 2023.\nAuthor, “The FTC’s Punctuated Equilibrium,” ABA Antitrust Magazine, September 2023.\nAuthor, “The FTC’s COPPA Conundrum: Ambiguities in the Rule and a Dearth of Authoritative Guidance Leave the Agency Vulnerable to Legal Challenges” ABA Antitrust Magazine, September 9, 2022.\nAuthor, “Antitrust and Consumer Protection at Last Converge,” Corporate Counsel, April 27, 2022.\nQuoted in, “CFPB May Fill Enforcement Gap After FTC’s High Court Loss,” Law360, May 6, 2021.\nQuoted in, “By the Numbers: 5 Practices That Could Drive Big Law in 2021,” Bloomberg Law, December 23, 2020.\nQuoted in, “‘Hipster Antitrust’ Comes for Joe Biden,” New York Times, November 13, 2020.\n“A Watershed Moment? What Comes Next for the FTC in the Wake of AMG,” ABA Antitrust Magazine, August 9, 2020.\n“The Intersection of Antitrust and the False Claims Act,” Headnotes, Dallas Bar Association, June 2020.\n“Unpacking the New FTC/DOJ Draft Vertical Merger Guidelines,” WLF Legal Pulse, March 9, 2020.\n“Seventh Circuit Sets Up Potential Supreme Court Review of FTC Monetary Relief Authority,” ABA Antitrust Magazine, December 12, 2019.\n“Next Stop, Supreme Court? Seventh Circuit Goes Its Own Way on FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, September 3, 2019.\n“Taking Stock of FTC Cybersecurity Enforcement After the Equifax Settlement,” WLF Legal Pulse, August 7, 2019.\n“Ninth Circuit Judges Call for En Banc Review of FTC’s Authority to Obtain Monetary Relief,” WLF Legal Pulse, January 15, 2019.\nCo-author, “Lessons from FTC’s Loss in, and Subsequent Abandonment of, DirecTV Advertising Case,” WLF Legal Pulse, October 23, 2018.\nCo-author, “Are Disgorgement’s Days Numbered? Kokesh v. SEC May Foreshadow Curtailment of the FTC’s Authority to Obtain Monetary Relief,” ABA Antitrust Magazine, Spring 2018.\n“Will Kokesh v. FTC Put a Kink in the Federal Trade Commission’s Disgorgement Hose?” WLF Legal Pulse, July 10, 2017.\n“Antitrust Scrutiny of Pharmaceutical Product Hopping,” ABA Antitrust Magazine, Fall 2013.\n“When Mergers Become a Private Matter: An Updated Antitrust Primer,” ABA Antitrust Magazine, Spring 2012.\n“Evaluating Mergers Between Potential Competitors Under the New Horizontal Merger Guidelines,” ABA Antitrust Magazine, Fall 2010.\n“The Complexities of Litigating Generic Drug Exclusion Claims in the Antitrust Class Action Context,” ABA Antitrust Magazine, Spring 2010.\n“Change?: Merger Enforcement in the New Administration,” The Advocate, Summer 2009.\n“Deterring ‘Patent Ambush’ in Standard Setting: Lessons from Rambus and Qualcomm,” ABA Antitrust Magazine, Summer 2009.\n“The FTC’s N-Data Consent Order: A Missed Opportunity to Clarify Antitrust in Standard Setting,” ABA Antitrust Magazine, Summer 2008.\n“Avoiding the Scarlet ‘S’: The Modern Challenges of Document Preservation and Destruction,” The American Lawyer, June 2005.\n“The Art of Destruction,” The American Lawyer, September 2004.\n“Standard Setting and Exclusionary Conduct: The Role of Antitrust in Policing Unilateral Abuses of a Standard-Setting Process,” Antitrust, 2004.\n“Administrative Litigation at the FTC: Past, Present, and Future,” Antitrust Law Journal, 2003.\n“Noerr Immunity for Sponsoring Litigation: From Burlington Northern to Baltimore Scrap,” Antitrust, 2001.\n“Coping with the Antitrust Risks of Technological Integration,” Antitrust Law Journal, 2000.\n“Disaggregation of Antitrust Damages,” Antitrust Law Journal, 1997.\n“Post-Chicago Economics,” Antitrust Law Journal, 1995.\n Partner Ranked Band 1 for Antitrust, Texas Chambers USA, 2007–2023 Top ranked for Antitrust USA Chambers Global, 2020–2023 Named a “Litigation Star” for Intellectual Property, Competition/Antitrust, Appellate, and Commercial work Benchmark Litigation, 2023 Named “Highly Recommended (Texas)” Global Competition Review, 2022 Named “Life Sciences Star” in Antitrust (2022) and Competition and Antitrust (2018–2019) LMG Life Sciences Named as one of “500 Leading Litigators in America” Lawdragon, 2022 and 2024 Listed Who’s Who Legal in Competition, 2021 Named “Litigation: Antitrust Lawyer of the Year” The Best Lawyers in America, 2019 Named “Antitrust Lawyer of the Year” The Best Lawyers in America, 2015 and 2018 Listed in “All-Star List” BTI Services, 2017 Named “Mergers and Acquisitions and Antitrust Trailblazer” National Law Journal, 2015 Named “National Antitrust MVP” Law360, 2015 Texas A\u0026amp;M University Texas A\u0026amp;M School of Law University of Chicago University of Chicago Law School U.S. Court of Appeals for the Federal Circuit U.S. Court of Appeals for the Third Circuit U.S. Court of Appeals for the Fifth Circuit U.S. District Court for the Northern District of Texas U.S. District Court for the Southern District of Texas District of Columbia Texas Senior Courts of England and Wales Current Practicing Certificate in Victoria (Australia) Judicial Clerk, Patrick E. Higginbotham, U.S Court of Appeals, 5th Circuit Litigation\nIn re Namenda Indirect Purchaser Antitrust Litigation (S.D.N.Y.) – Represented Forest Labs. and affiliates in this still-ongoing indirect purchaser antitrust class action involving allegations of “product hopping” and a challenged “reverse payment” patent settlement. In re Restasis Antitrust Litigation (E.D.N.Y.) – Served as lead counsel for Allergan in this consolidated MDL antitrust class action involving complex patent- and FDA-related monopolization claims predicated on allegations of delayed entry of generic drugs. Cases settled favorably for defendants after class certification and summary judgment briefing and arguments. U.S. ex rel. Silbersher v. Allergan (N.D. Cal.) – Served as lead counsel for Allergan in this False Claims Act litigation in which a private relator sought to assert claims of alleged fraud against the government predicated on a patent-related theory and assertions of delayed generic drug entry. In re JUUL Labs., Inc. Antitrust Litigation (N.D. Cal.) – Served as lead antitrust counsel in this still-ongoing consolidated MDL antitrust class action challenging an allegedly unlawful agreement. U.S. v. AT\u0026amp;T (C.D. Cal.) – Served as lead antitrust counsel for AT\u0026amp;T in this suit in which DOJ asserted that AT\u0026amp;T’s DirecTV unit engaged in improper coordination and information sharing relating to pay TV distributors’ negotiations with the provider of sports-related television content; case settled on highly favorable terms after full briefing of AT\u0026amp;T’s motion to dismiss. FTC v. Lending Club (N.D. Cal.) – Served as lead counsel for Lending Club in this suit in which the FTC asserted multiple consumer protection-based claims relating to Lending Club’s marketing and advertising practices and privacy-related compliance; argued summary and obtained partial victories; case settled favorably. U.S. v. AT\u0026amp;T (D.D.C. \u0026amp; D.C. Cir.) – Played an important role on the trial team in this landmark case in which AT\u0026amp;T defeated a DOJ antitrust challenge to the company’s US$85 billion acquisition of Time Warner, an outcome that was later affirmed on appeal in the D.C. Circuit. SureShot v. Topgolf (S.D. Tex. \u0026amp; 5th Cir.) – Served as lead counsel for Topgolf in this antitrust suit asserting monopolization claims; obtained full dismissal of all claims by district court and unanimous affirmance. Cipla v. Amgen (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Amgen in this monopolization suit brought by a generic drug competitor; argued preliminary injunction motion and participated in later interlocutory appeal. Shire v. Allergan (D. N.J.) – Served as lead counsel for Allergan in this competitor monopolization suit involving alleged bundling and exclusive dealing practices; argued successful motion to dismiss. Hartig v. Allergan (D. Del. \u0026amp; 3d Cir.) – Served as lead counsel for Allergan in this putative antitrust class action asserting that Allergan delayed generic entry through alleged “product hopping”; argued successful motion to dismiss and later defended that ruling through oral argument before the Third Circuit; case was settled on highly favorable terms after remand to district court. Apotex v. Allergan (D. Del.) – Served as lead counsel for Allergan in this competitor monopolization suit predicated on claims of unlawful “product hopping”; obtained highly favorable settlement after the close of fact and expert discovery. Amphastar v. Sanofi-Aventis (C.D. Cal.) – Served as lead counsel for Sanofi in this competitor monopolization suit asserting patent- and FDA-related antitrust claims; successfully argued for dismissal of all claims. U.S. ex rel. Amphastar v. Sanofi-Aventis (C.D. Cal \u0026amp; 9th Cir.) – Served as lead counsel for Sanofi in this suit in which a competing generic drug company, having had its own antitrust claims dismissed, sought to assert related False Claims Act claims as a purported relator; case was fully dismissed by the district court and the outcome was affirmed by the Ninth Circuit. FTC v. Commerce Planet (9th Cir.) – Represented former Commerce Planet CEO in this FTC consumer protection suit in which the client, represented by prior counsel, was subjected to a judgment with significant personal liability. Stanwood v. Mary Kay Cosmetics (C.D. Cal.) – Served as lead counsel for Mary Kay in this putative class action case alleging fraud and unfair competition relating to the company’s prior participation in industry pledge not to conduct animal-based testing; obtained full dismissal of all claims. Avery Dennison v. 3M Corp. (D. Minn.) – Served as lead antitrust counsel for 3M in this competitor suit alleging that 3M monopolized markets through wrongful patent-related conduct in the context of industry standard-setting activities; case settled on highly favorable terms following the close of fact and expert discovery. In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) – Served as lead counsel for Biovail in this antitrust class action alleging patent-related monopolization and conspiracy claims. Todd v. Exxon, et al. (S.D.N.Y.) – Served as lead antitrust counsel for Phillips Petroleum in this putative antitrust class action alleging conspiracy claims based on asserted improper sharing of salary and benefits information. Neon Systems v. BMC Software (Tex. Civ.) – Served as lead antitrust counsel for BMC Software in this competitor suit alleging that BMC had monopolized markets through unlawful pricing and bundling practices; case settled favorably shortly before trial. Atlantic Coast Airlines v. Mesa Airlines (D.D.C.) – Served as trial counsel for Atlantic Coast Airlines in this successful antitrust action obtaining a preliminary injunction barring United Airlines and Mesa Airlines from proceeding with a contemplated business arrangement. Continental Forge v. Sempra Energy (Sup. Ct. Cal.) – Represented Sempra Energy and affiliates in this suit alleging antitrust conspiracy claims. Longhorn Partners Pipeline Co. v. Holly Corp. (W.D. Tex.) – Represented Holly Corp. in this antitrust suit alleging monopolization of West Texas petroleum pipelines. U.S. v. AMR Corp. (D. Kansas) – Represented American Airlines and parent AMR in this government antitrust suit alleging predatory pricing; case resolved through summary judgment for defendants.* Litton Systems v. Honeywell (C.D. Cal. \u0026amp; 9th Cir.) – Represented Honeywell in this competitor monopolization suit alleging that Honeywell improperly excluded competition in the market for commercial avionics systems; successfully argued motion for directed verdict on majority of claims at issue. Continental Airlines v. American Airlines (S.D. Tex.) –Represented American Airlines in this suit alleging improper predatory pricing relating to American’s introduction of a new fare structure; obtained favorable jury verdict. Government Investigations\nKurbo/WW Inc. – Lead counsel for WW International and affiliate Kurbo in connection with FTC privacy (COPPA) investigation and settlement. Google/Fitbit – Counsel for Fitbit in connection with DOJ investigation of Google’s successful US$2.1 billion acquisition of Fitbit. AT\u0026amp;T/Time Warner – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$85 billion acquisition of Time Warner. AT\u0026amp;T/DirecTV – Counsel for AT\u0026amp;T in connection with DOJ investigation of the company’s successful US$48 billion acquisition of DirecTV. Facebook – Lead counsel for Facebook in connection with FTC investigation relating to compliance with prior 2012 consent order prescribing certain privacy-related standards and practices; also lead counsel for the company in connection with the prior 2012 FTC privacy investigation. Bazaarvoice – Lead counsel for Bazaarvoice relating to DOJ antitrust and order compliance investigations. Ticketmaster/LiveNation – Lead counsel for Ticketmaster in connection with DOJ investigation of the company’s US$2.5 billion acquisition of LiveNation. Williams Cos. – Lead antitrust counsel for Williams in connection with proposed US$38 billion acquisition by Energy Transfer Equity LP. Leon Max/Max Studios – Lead counsel for Max Studios in connection with FTC investigation of asserted violations of prior FTC consent order imposing restrictions on advertising of textile content of retail garments. ValueClick – Lead counsel for ValueClick in connection with FTC consumer protection claims involving various privacy and online advertising issues. Allergan – Lead counsel for Allergan in connection with FTC investigation of the company’s successful US$3.2 billion acquisition of Inamed Corp. Watson Wyatt – Lead counsel for Watson Wyatt in connection with DOJ investigation of the company’s successful US$3.5 billion acquisition of Towers Perrin. United Defense – Lead counsel for United Defense in DOJ investigation of BAe’s successful US$4.2 billion acquisition of UDI. Ancestry.com – Lead counsel for Ancestry.com in connection with FTC investigation of the company’s successful acquisition of Archive.com. Endocare – Lead counsel for Endocare in connection with FTC investigation of proposed merger with Galil Medical. DiedrichCoffee – Lead counsel for Diedrich in FTC investigation of successful merger with Green Mountain Coffee Roasters. Numerous other representations as lead counsel in non-public government investigations, including many FTC consumer protection matters, where successful results leading to closures of the investigations caused them to remain non-public matters.","searchable_name":"M. Sean Royall","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":446362,"version":1,"owner_type":"Person","owner_id":5964,"payload":{"bio":"\u003cp\u003eKimberly Rai is an attorney\u0026nbsp;in the Government Matters Group\u0026nbsp;in the firm's New York office and is a member of\u0026nbsp;King \u0026amp; Spalding's healthcare transactional and regulatory practice.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKimberly's corporate and transactional practice focuses on advising clients on matters relating to formation, governance, mergers and acquisitions, joint ventures, corporate restructuring, and federal, state, and local tax exemption.\u003c/p\u003e\n\u003cp\u003eIn addition to her transactional experience, Kimberly counsels healthcare industry clients on regulatory and compliance matters, including healthcare facility, pharmacy and laboratory licensure and certification, corporate practice of medicine, voluntary disclosures and fraud and abuse laws.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eKimberly's clients include for-profit and not-for-profit organizations such as hospitals, integrated healthcare delivery systems, academic medical centers, managed care organizations, pharmaceutical and life sciences companies, management companies, nursing homes, charitable and religious organizations, and physician practices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eKimberly began her career in-house and draws on this experience to develop innovative and effective legal strategies to further her client\u0026rsquo;s goals. Prior to joining King \u0026amp; Spalding, Kimberly practiced in the healthcare group at another\u0026nbsp;\u003cem\u003eAm Law 100\u003c/em\u003e\u0026nbsp;firm.\u003c/p\u003e","slug":"kimberly-rai","email":"krai@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":24,"guid":"24.capabilities","index":0,"source":"capabilities"},{"id":27,"guid":"27.capabilities","index":1,"source":"capabilities"},{"id":112,"guid":"112.capabilities","index":2,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":3,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":4,"source":"capabilities"},{"id":826,"guid":"826.smart_tags","index":5,"source":"smartTags"}],"is_active":true,"last_name":"Rai","nick_name":"Kimberly","clerkships":[],"first_name":"Kimberly","title_rank":9999,"updated_by":202,"law_schools":[{"id":722,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":null},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eKimberly Rai is an attorney\u0026nbsp;in the Government Matters Group\u0026nbsp;in the firm's New York office and is a member of\u0026nbsp;King \u0026amp; Spalding's healthcare transactional and regulatory practice.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eKimberly's corporate and transactional practice focuses on advising clients on matters relating to formation, governance, mergers and acquisitions, joint ventures, corporate restructuring, and federal, state, and local tax exemption.\u003c/p\u003e\n\u003cp\u003eIn addition to her transactional experience, Kimberly counsels healthcare industry clients on regulatory and compliance matters, including healthcare facility, pharmacy and laboratory licensure and certification, corporate practice of medicine, voluntary disclosures and fraud and abuse laws.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eKimberly's clients include for-profit and not-for-profit organizations such as hospitals, integrated healthcare delivery systems, academic medical centers, managed care organizations, pharmaceutical and life sciences companies, management companies, nursing homes, charitable and religious organizations, and physician practices.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eKimberly began her career in-house and draws on this experience to develop innovative and effective legal strategies to further her client\u0026rsquo;s goals. Prior to joining King \u0026amp; Spalding, Kimberly practiced in the healthcare group at another\u0026nbsp;\u003cem\u003eAm Law 100\u003c/em\u003e\u0026nbsp;firm.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":8805}]},"capability_group_id":2},"created_at":"2026-03-02T22:00:00.000Z","updated_at":"2026-03-02T22:00:00.000Z","searchable_text":"Rai{{ FIELD }}Kimberly Rai is an attorney in the Government Matters Group in the firm's New York office and is a member of King \u0026amp; Spalding's healthcare transactional and regulatory practice. \nKimberly's corporate and transactional practice focuses on advising clients on matters relating to formation, governance, mergers and acquisitions, joint ventures, corporate restructuring, and federal, state, and local tax exemption.\nIn addition to her transactional experience, Kimberly counsels healthcare industry clients on regulatory and compliance matters, including healthcare facility, pharmacy and laboratory licensure and certification, corporate practice of medicine, voluntary disclosures and fraud and abuse laws. \nKimberly's clients include for-profit and not-for-profit organizations such as hospitals, integrated healthcare delivery systems, academic medical centers, managed care organizations, pharmaceutical and life sciences companies, management companies, nursing homes, charitable and religious organizations, and physician practices. \nKimberly began her career in-house and draws on this experience to develop innovative and effective legal strategies to further her client’s goals. Prior to joining King \u0026amp; Spalding, Kimberly practiced in the healthcare group at another Am Law 100 firm. Counsel New York University New York University School of Law Fordham University Fordham University School of Law New Jersey New York New York Bar Association","searchable_name":"Kimberly Rai","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":435752,"version":1,"owner_type":"Person","owner_id":7220,"payload":{"bio":"\u003cp\u003eJoshua E. Roberts is a trial litigator whose practice focuses on complex commercial and business litigation. He represents publicly traded and closely held companies, private equity firms, financial institutions, executives, and board members in high-stakes disputes in federal and state courts. He has extensive experience in a broad array of matters, including contract disputes, fiduciary duty claims, mergers and acquisitions disputes, class actions, multidistrict litigation, civil RICO violations, and bankruptcy adversary proceedings. He also represents companies and individuals in government enforcement actions and sensitive investigations conducted by the U.S. Department of Justice and various state attorneys general.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Roberts clerked for the Honorable Arthur D. Spatt of the U.S. District Court for the Eastern District of New York. He is a graduate of the University of Pennsylvania Law School and holds a Master of Business Administration, with a concentration in Finance, from the Wharton School of the University of Pennsylvania. He earned his Bachelor of Arts, magna cum laude, from the University of Pennsylvania.\u003c/p\u003e","slug":"joshua-roberts","email":"jroberts@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[{"id":4124}]},"expertise":[{"id":5,"guid":"5.capabilities","index":0,"source":"capabilities"},{"id":74,"guid":"74.capabilities","index":1,"source":"capabilities"},{"id":1,"guid":"1.capabilities","index":2,"source":"capabilities"},{"id":38,"guid":"38.capabilities","index":3,"source":"capabilities"},{"id":3,"guid":"3.capabilities","index":4,"source":"capabilities"},{"id":19,"guid":"19.capabilities","index":5,"source":"capabilities"},{"id":7,"guid":"7.capabilities","index":6,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":7,"source":"capabilities"},{"id":15,"guid":"15.capabilities","index":8,"source":"capabilities"},{"id":11,"guid":"11.capabilities","index":9,"source":"capabilities"},{"id":107,"guid":"107.capabilities","index":10,"source":"capabilities"},{"id":109,"guid":"109.capabilities","index":11,"source":"capabilities"},{"id":103,"guid":"103.capabilities","index":12,"source":"capabilities"},{"id":129,"guid":"129.capabilities","index":13,"source":"capabilities"}],"is_active":true,"last_name":"Roberts","nick_name":"Joshua","clerkships":[{"name":"Law Clerk, Hon. Arthur D. Spatt, U.S. District Court for the Eastern District of New York","years_held":"2017 - 2019"}],"first_name":"Joshua","title_rank":9999,"updated_by":202,"law_schools":[{"id":2282,"meta":{"degree":"J.D.","honors":"","is_law_school":"1","graduation_date":"2015-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"Eric","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":"Joshua Eric Roberts is a counsel of our Business Litigation Practice Group. Read more.","primary_title_id":14,"translated_fields":{"en":{"bio":"\u003cp\u003eJoshua E. Roberts is a trial litigator whose practice focuses on complex commercial and business litigation. He represents publicly traded and closely held companies, private equity firms, financial institutions, executives, and board members in high-stakes disputes in federal and state courts. He has extensive experience in a broad array of matters, including contract disputes, fiduciary duty claims, mergers and acquisitions disputes, class actions, multidistrict litigation, civil RICO violations, and bankruptcy adversary proceedings. He also represents companies and individuals in government enforcement actions and sensitive investigations conducted by the U.S. Department of Justice and various state attorneys general.\u0026nbsp;[[--readmore--]]\u003c/p\u003e\n\u003cp\u003eMr. Roberts clerked for the Honorable Arthur D. Spatt of the U.S. District Court for the Eastern District of New York. He is a graduate of the University of Pennsylvania Law School and holds a Master of Business Administration, with a concentration in Finance, from the Wharton School of the University of Pennsylvania. He earned his Bachelor of Arts, magna cum laude, from the University of Pennsylvania.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":12978}]},"capability_group_id":3},"created_at":"2025-08-25T20:29:54.000Z","updated_at":"2025-08-25T20:29:54.000Z","searchable_text":"Roberts{{ FIELD }}Joshua E. Roberts is a trial litigator whose practice focuses on complex commercial and business litigation. He represents publicly traded and closely held companies, private equity firms, financial institutions, executives, and board members in high-stakes disputes in federal and state courts. He has extensive experience in a broad array of matters, including contract disputes, fiduciary duty claims, mergers and acquisitions disputes, class actions, multidistrict litigation, civil RICO violations, and bankruptcy adversary proceedings. He also represents companies and individuals in government enforcement actions and sensitive investigations conducted by the U.S. Department of Justice and various state attorneys general. \nMr. Roberts clerked for the Honorable Arthur D. Spatt of the U.S. District Court for the Eastern District of New York. He is a graduate of the University of Pennsylvania Law School and holds a Master of Business Administration, with a concentration in Finance, from the Wharton School of the University of Pennsylvania. He earned his Bachelor of Arts, magna cum laude, from the University of Pennsylvania. Joshua Eric Roberts counsel Counsel University of Pennsylvania University of Pennsylvania Law School University of Pennsylvania University of Pennsylvania Law School Wharton School of the University of Pennsylvania  U.S. Court of Appeals for the Third Circuit U.S. District Court for the Eastern District of New York U.S. District Court for the Southern District of New York U.S. District Court for the District of New Jersey New Jersey New York Law Clerk, Hon. Arthur D. Spatt, U.S. District Court for the Eastern District of New York","searchable_name":"Joshua Eric Roberts","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null},{"id":444722,"version":1,"owner_type":"Person","owner_id":6682,"payload":{"bio":"\u003cp\u003eSamuel Rubinstein is an associate in King \u0026amp; Spalding\u0026rsquo;s Global Human Capital and Compliance practice. As a former National Labor Relations Board attorney with experience on both the Board-side and the General Counsel-side of the agency, Samuel represents employers in all facets of labor relations. With his insider perspective, Samuel guides employers through the National Labor Relations Act and its unique rules and regulations. Samuel also counsels\u0026nbsp;employers on day-to-day employment law issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Samuel served as an Attorney-Adviser to National Labor Relations Board Member Marvin E. Kaplan. He counseled Member Kaplan about unfair labor practice cases that were before the Board for adjudication\u0026nbsp;and drafted decisions on the National Labor Relations Board's behalf. During his time at the Board, Samuel also served a detail assignment with one of the regional offices, where he investigated and litigated unfair labor practices. Previously, Samuel clerked for a federal district court judge and was a labor and employment associate at an international law firm.\u003c/p\u003e","slug":"samuel-rubinstein","email":"srubinstein@kslaw.com","phone":null,"matters":null,"taggings":{"tags":[],"meta_tags":[]},"expertise":[{"id":121,"guid":"121.capabilities","index":0,"source":"capabilities"},{"id":15,"guid":"15.capabilities","index":1,"source":"capabilities"},{"id":24,"guid":"24.capabilities","index":2,"source":"capabilities"},{"id":81,"guid":"81.capabilities","index":3,"source":"capabilities"}],"is_active":true,"last_name":"Rubinstein","nick_name":"Samuel","clerkships":[{"name":"Judicial Clerk, Lawrence E. Kahn, U.S. District Court for the Northern District of New York","years_held":"2021 - 2022"}],"first_name":"Samuel","title_rank":9999,"updated_by":202,"law_schools":[{"id":824,"meta":{"degree":"J.D.","honors":"cum laude","is_law_school":"1","graduation_date":"2019-01-01 00:00:00"},"order":1,"pin_order":null,"pin_expiration":null}],"middle_name":"Isaak","name_suffix":"","recognitions":null,"linked_in_url":null,"seodescription":null,"primary_title_id":75,"translated_fields":{"en":{"bio":"\u003cp\u003eSamuel Rubinstein is an associate in King \u0026amp; Spalding\u0026rsquo;s Global Human Capital and Compliance practice. As a former National Labor Relations Board attorney with experience on both the Board-side and the General Counsel-side of the agency, Samuel represents employers in all facets of labor relations. With his insider perspective, Samuel guides employers through the National Labor Relations Act and its unique rules and regulations. Samuel also counsels\u0026nbsp;employers on day-to-day employment law issues.[[--readmore--]]\u003c/p\u003e\n\u003cp\u003ePrior to joining King \u0026amp; Spalding, Samuel served as an Attorney-Adviser to National Labor Relations Board Member Marvin E. Kaplan. He counseled Member Kaplan about unfair labor practice cases that were before the Board for adjudication\u0026nbsp;and drafted decisions on the National Labor Relations Board's behalf. During his time at the Board, Samuel also served a detail assignment with one of the regional offices, where he investigated and litigated unfair labor practices. Previously, Samuel clerked for a federal district court judge and was a labor and employment associate at an international law firm.\u003c/p\u003e"},"locales":["en"]},"secondary_title_id":null,"upload_assignments":{"headshot":[{"id":11895}]},"capability_group_id":2},"created_at":"2026-01-02T16:02:20.000Z","updated_at":"2026-01-02T16:02:20.000Z","searchable_text":"Rubinstein{{ FIELD }}Samuel Rubinstein is an associate in King \u0026amp; Spalding’s Global Human Capital and Compliance practice. As a former National Labor Relations Board attorney with experience on both the Board-side and the General Counsel-side of the agency, Samuel represents employers in all facets of labor relations. With his insider perspective, Samuel guides employers through the National Labor Relations Act and its unique rules and regulations. Samuel also counsels employers on day-to-day employment law issues.\nPrior to joining King \u0026amp; Spalding, Samuel served as an Attorney-Adviser to National Labor Relations Board Member Marvin E. Kaplan. He counseled Member Kaplan about unfair labor practice cases that were before the Board for adjudication and drafted decisions on the National Labor Relations Board's behalf. During his time at the Board, Samuel also served a detail assignment with one of the regional offices, where he investigated and litigated unfair labor practices. Previously, Samuel clerked for a federal district court judge and was a labor and employment associate at an international law firm. Senior Associate CUNY Bernard M Baruch College  Harvard University Harvard Law School New York Judicial Clerk, Lawrence E. Kahn, U.S. District Court for the Northern District of New York","searchable_name":"Samuel Isaak Rubinstein","is_active":true,"featured":null,"publish_date":null,"expiration_date":null,"blog_featured":null,"published_by":202,"capability_group_featured":null,"home_page_featured":null}]}}